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Abstract 
Oral cancer ranks as the sixth most common cancer in the world, and despite advances in surgical 
techniques over the past 30 years, has a five year survival rate of only 50%. The poor survival rate 
is partly attributed to the fact that the majority of patients are diagnosed at advanced stages of the 
disease. Early detection and intervention is therefore important for improving patient prognosis as 
invasive and disfiguring treatment that has high morbidity and mortality can be avoided. Ideally, 
oral potentially malignant disorders (OPMDs) are detected and monitored before they can progress 
to cancer. However, OPMDs can be difficult to detect using standard operatory lights, as some 
lesions may have only very subtle changes in colour and texture. This has led to the development 
and use of various visualisation adjuncts that claim to improve the clinician’s ability to detect 
lesions. 
One visualisation adjunct that can be used intraorally is Narrow Band Imaging (NBI), which is an 
endoscopic technique that utilises filtered blue and green light to highlight the mucosal surface 
texture and underlying vasculature. The ability to enhance vasculature makes NBI a useful 
technology for highlighting neoplastic lesions that may not be clinically evident with white light 
alone, as angiogenesis is an early occurrence in carcinogenesis. Use of NBI in the oral cavity has 
been a fairly recent development, and thus the literature regarding its efficacy and usefulness is 
relatively limited. 
The first experimental chapter aimed to investigate the efficacy of NBI for aiding the detection of 
OPMDs in a prospective series of patients with at least one white, red or red-white oral mucosal 
lesion. All patients underwent a conventional oral examination, followed by an exam using the 
white light mode then the NBI mode of a NBI system. A total of 272 lesions from 95 patients were 
observed. When using conventional oral examination as the gold standard, NBI had 100%, 74.63%, 
92.38%, 100% and 93.77% sensitivity, specificity, positive predictive value, negative predictive 
value and accuracy respectively for the detection of OPMDs. NBI aided the detection of 24 lesions 
undetected by conventional oral examination and 13 lesions undetected by white light endoscopy. 
Unfortunately, surgical intervention for the treatment of OPMDs and oral cancer cannot be 
completely avoided despite the emphasis of early detection and monitoring. When surgery is 
indicated, a key factor for having a good prognosis is to have clean resection margins. Current 
methods for delineating the margin between healthy and diseased tissue may not necessarily result 
in a clean margin at a molecular level, even though they may appear healthy at a histological level. 
The second experimental chapter aimed to correlate mRNA and microRNA expression profiles at 
the primary tumour margins of oral cavity squamous cell carcinoma defined by NBI and white light. 
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Three samples were taken from each of the eighteen resected oral squamous cell carcinomas – one 
from the NBI margin, white light margin and centre of the tumour. RNA was isolated from each 
sample and hybridised to mRNA and miRNA gene expression microarrays. A total of 4 794 genes 
and 137miRNAs were found to be differentially expressed. The type of miRNAs and genes 
expressed at the tumour was different compared to at the NBI margin – specifically, the NBI margin 
was more likely to contain molecularly normal cells. When integrating differentially expressed 
miRNA with differentially expressed mRNA, there were 91 potential miRNA-mRNA pairs (28 
miRNA with 87 genes) identified. Several of the miRNAs and genes have been implicated in anti-
apoptosis, tumorigenesis and metastasis. 
These studies demonstrate that NBI has great utility as a visualisation adjunct for detecting OPMDs 
and OSCCs, as it can aid the delineation of healthy tissue from diseased at both tissue and 
molecular levels. The use of NBI for monitoring OPMDs and determining tumour resection margins 
may improve the overall survival rate of OSCCs. 
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1.1 Abstract 
Objective: Narrow band imaging (NBI) is an endoscopic technique that enhances the mucosal 
surface texture, and mucosal and submucosal vascular morphology. This paper systematically 
reviews the available literature regarding the efficacy of NBI for the detection and monitoring of 
potentially malignant and malignant lesions in the oral cavity and oropharynx. 
Methods: Databases searched included PubMed, EMBASE, Web of Science and Scopus (to 
September 2013). Additional articles were found by conducting an author publication search using 
PubMed and by scanning the reference lists of relevant articles. Only trials that investigated and 
evaluated the effectiveness of both white light (WL) and NBI for aiding the detection of only oral 
potentially malignant lesions, oral squamous cell carcinomas and/or oropharyngeal squamous cell 
carcinomas were considered for this review. Two reviewers (ANV and CSF) independently 
assessed retrieved articles against the criteria, and included articles underwent data extraction and 
risk of bias assessment. 
Results: Two studies, one retrospective and one prospective, met the inclusion criteria. The 
sensitivity, specificity, positive predictive value, negative predictive value and accuracy for white 
light ranged between 56-96%, 60-100%, 33-100%, 87-99% and 66-89% respectively, whereas it 
was 87-96%, 94-98%, 73-96%, 97-98% and 92-97% respectively for NBI.  
Conclusion: While more research is required to determine the full value of NBI, it has great 
potential in accurately aiding the detection and assessment of neoplastic lesions, and influencing 
how these lesions are managed. 
 
 
 
Keywords: narrow band imaging; oral cancer; oropharyngeal cancer; oral squamous cell carcinoma; 
oral potentially malignant lesions; detection; surveillance 
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1.2 Introduction 
Oral and pharyngeal cancers combined rank within the top ten most common malignancies in the 
world for men, with an estimated global incidence of oral cancer alone at approximately 275 000 
[1]. Over 90% of oral cancers affecting the lips, gingiva, tongue, buccal mucosa, floor of mouth and 
hard palate arise from the squamous epithelium and are thus termed oral squamous cell carcinomas 
(OSCCs) [2,3]. Conversely, neoplasms originating from the epithelial lining of oropharynx are 
called oropharyngeal squamous cell carcinomas (OPSCCs) [1]. Patients with OSCCs are typically 
males over 40 years of age with a history of regular exposure to aetiological risk factors such as 
tobacco products, alcohol, betel quid or micronutrient deficiency [2,4]; however, younger patients 
with lower cumulative tobacco or alcohol exposure are increasingly presenting with OSCC or 
OPSCC [2]. These early-onset OSCCs or OPSCCs are often located in the base of the tongue, 
tonsils and oropharynx, and are associated with the human papillomavirus infection [1,2,5,6].  
Despite advances in the treatment of OSCC over the past 30 years, the five year survival rate has 
remained at around 50% but can be as low as 15% when patients present with advanced cancers that 
have metastasized to the cervical lymph nodes [2]. The presence of synchronous or metachronous 
OSCCs due to the field cancerisation effect further reduces prognosis [7-9].  Early detection of 
OSCCs at the dysplasia or carcinoma in situ (CIS) stages improves morbidity and mortality as there 
is a very low risk of metastasis [10-12]. Consequently, painful, invasive and disfiguring treatment 
that often results in loss of function and reduced quality of life can be avoided [12,13]. However, it 
can be difficult to detect OSCC in the early stages as they are not only relatively asymptomatic, but 
can also have very subtle changes in the epithelium that make them difficult to visualise with 
standard visualisation techniques using white light (WL) inspection [12,14]. These mucosal changes 
may appear as patches of white, red, or speckled red-white, and are called leukoplakia, 
erythroplakia or erythro-leukoplakia (speckled erythroplakia) respectively when there is no clinical 
or histopathological diagnosis [2]. Therefore, research into technology and techniques that can 
enhance visualisation has resulted in the development of several visualisation methods – one of 
which is narrow band imaging (NBI).  
NBI (Olympus Medical Systems Corporation, Tokyo, Japan) is an endoscopic technique that 
provides real-time on-demand optical image enhancement of the mucosal and submucosal vascular 
morphology and mucosal surface texture. The technology utilises the concept that the wavelength of 
light determines the depth of penetration [15,16]. In NBI mode, two optical filters placed in front of 
WL select two narrow bands of light in the blue and green spectrum. Blue light between 400 and 
430 nm (centred at 415 nm) corresponds to the peak absorption spectrum of haemoglobin, and can 
therefore highlight the capillary bed and intrapapillary capillary loop (IPCL) pattern in the 
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superficial mucosa by making them appear brown. Thicker blood vessels in the deeper mucosa and 
submucosa are enhanced by green light between 525 and 555 nm (centred at 540 nm), and appear 
cyan [15-18]. A charge coupled device (CCD) at the tip of the endoscope captures the reflected 
light, which is then reconstructed to produce a coloured NBI image that is displayed on a monitor. 
Switching between WL mode and NBI mode simply involves pressing a button on the 
videoendoscope, video camera or monitor console [10]. Magnifying endoscopy, which can enhance 
morphological and colour changes in the mucosa and allow for clearer visualisation of 
microvascular structures, is also possible with the two commercially available NBI systems [15,19]. 
The red-green-blue sequential NBI endoscopes (Evis Lucera 260 Spectrum) can optically magnify 
images up to 80 times and is considered to give clearer images, whereas the colour CCD 
endoscopes (Evis Exera II and Evis Exera III) are coupled with digital zoom at 1.2 and 1.5 times 
magnification. Both are capable of maintaining excellent resolution even when the endoscope tip is 
as close as 2 mm from the mucosal surface due to their physical zoom property [19].  
As angiogenesis occurs early in the carcinogenesis continuum, the distinct microvasculature 
architecture associated with potentially malignant and malignant lesions can be used to differentiate 
these lesions from normal mucosa [13,14,20]. Areas of neoplasia are typically characterised by 
well-demarcated brownish areas with scattered spots, whereas inflammatory lesions have ill-
demarcated borders [17,21]. However, NBI has been designed to enhance microvascular 
morphology, and can therefore be used to detect vascular changes such as the degree of dilation, 
meandering, tortousity and calibre of IPCLs [13,20]. Typically, a separate IPCL classification for 
oral mucosa is used for oral lesions [21]. This classification is a simplified version of Inoue’s IPCL 
classification for oesophageal mucosa [20]. Normal mucosa has IPCL type I, and is characterised by 
regular brown dots when loops are perpendicular to the surface of the mucosa, or waved lines when 
parallel. Non-neoplastic lesions are either type II, which has a dilated and crossing IPCL pattern, or 
type III, which demonstrates an elongated and meandering IPCL pattern. Neoplastic lesions have 
type IV, which is characterised by large vessels, IPCL pattern destruction and the presence of 
angiogenesis. For all these classifications, the most advanced IPCL pattern determines the type of 
lesion when more than one pattern is present [20-22]. 
Although NBI is commonly used in the gastrointestinal, aerodigestive and urinary tracts, the use of 
this technology in the oral cavity to screen for oral potentially malignant lesions (OPMLs) and 
OSCC has only been a fairly recent development. Consequently, the literature regarding the use of 
NBI as a visualisation adjunct for screening potentially malignant and malignant lesions in the oral 
cavity and oropharynx is still limited. Nonetheless, NBI has demonstrated high sensitivity and 
specificity for aiding the detection of dysplasia and neoplasia elsewhere in the head and neck [23]. 
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In order to determine the benefits of NBI over traditional WL oral and oropharyngeal examination, 
this paper aims to systematically review the literature relating to the efficacy of NBI for the 
detection and surveillance of OPMLs, OSCCs and/or OPSCCs in patients who have or are at risk of 
having these types of lesions. 
 
 
1.3 Methods 
1.3.1 Criteria for considering studies for this review 
1.3.1.1 Types of studies 
Retrospective and prospective trials that investigated and evaluated the effectiveness of both WL 
and NBI for aiding the detection of only OPMLs, OSCCs and/or OPSCCs were included for this 
review. Studies had to have values for sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy for both lights, or had enough data reported that these 
could be calculated. Although publications had to be in English, there were no restrictions on 
publication date or publication status. 
1.3.1.2 Types of participants 
Participants who underwent examination with both conventional broadband WL and NBI, and had 
at least one detectable OPML, OSCC and/or OPSCC were included. 
1.3.1.3 Types of interventions 
Studies considered for inclusion had to have a WL comparison to NBI view, and this was typically 
the conventional broadband WL view of the NBI system. Lesions deemed suspicious for dysplasia, 
CIS, or carcinoma required histopathological assessment; however, this was not a requirement for 
non-suspicious lesions due to the ethical implications and feasibility regarding random biopsy 
sampling in every patient with negative clinical results. 
1.3.1.4 Types of outcome measures 
Although the primary outcome considered for this review was the efficacy of WL and NBI for 
aiding the detection and surveillance of OPMLs, OSCCs and/or OPSCCs, other outcome measures 
also considered included the effectiveness of the criteria used for determining the presence of 
dysplasia or neoplasia with NBI, correlations between IPCL patterns and diagnoses, advantages of 
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using NBI in the oral cavity and oropharynx, and limitations of the use of NBI in the oral cavity and 
oropharynx. 
 
1.3.2 Search strategy  
In order to retrieve relevant published English language studies, detailed search strategies were 
developed for each electronic database used (Figure 1.1and Figure 1.2). Databases searched 
included PubMed (to 18 September 2013), EMBASE (to 18 September 2013), Web of Science (to 
20 September 2013) and Scopus (to 30 September 2013) (Appendix I). In addition, PubMed was 
used to conduct an author publication search of all authors who contributed to articles that were 
potentially relevant. The reference lists of all relevant articles retrieved from the databases and from 
the author publication search were checked to identify other studies (see Figure 1.3).  
 
1.3.3 Data collection and analysis 
1.3.3.1 Selection of studies 
After duplicates were removed, two reviewers (ANV and CSF) independently scanned the titles and 
abstracts of all studies retrieved from the initial electronic database search for relevance. Full 
reports of potentially relevant studies were obtained for detailed assessment against the inclusion 
criteria (Figure 1.3). If necessary, authors of potentially relevant studies were contacted for 
clarification of data. Disagreements were resolved by discussion between the two reviewers. 
1.3.3.2 Data extraction 
All studies meeting the inclusion criteria underwent critical appraisal and data extraction using a 
modified data extraction form based on the Cochrane Consumers and Communication Review 
Group’s data extraction template. For consistency, one review author (ANV) was designated as the 
primary reviewer of all studies that required data extraction, and the second author (CSF) reviewed 
the extracted data. Differences between the two reviewers were settled by discussion. 
Data extracted from the selected studies included first author, publication year, country of origin, 
study type, demographic details of participants and the inclusion and exclusion criteria, details of 
the intervention and comparison types, details of the study design, and details of the reported 
outcomes – in particular, the sensitivity, specificity, PPV, NPV and accuracy for both WL and NBI.  
7 
 
 
Figure 1.1. PubMed search strategy using MeSH descriptors. 
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Figure 1.2. Basic structure for the keyword search strategy for EMBASE, Web of Science and Scopus databases.  
If necessary, slight modifications to the search strategy were made to suit each database. 
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1.3.3.3 Assessment of risk of bias 
Two reviewers (ANV and CSF) independently assessed the risk of bias for all studies included in 
this review using the updated version of the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2) tool. 
1.3.3.4 Data synthesis 
A meta-analysis of the data would have been conducted if there was a minimum of three suitable 
trials; otherwise results were described in narrative format.  
 
 
1.4 Results 
The initial search of the PubMed, EMBASE, Web of Science and Scopus databases (to September 
2013) revealed a total of 111 citations. After screening the titles and abstracts and removing 51 
duplicates and 55 irrelevant references, full reports of five papers were obtained for screening 
against the inclusion criteria. A further two studies were identified for potential inclusion – one 
found by searching the reference lists of retrieved review articles and the four potentially relevant 
papers [24], and the other by conducting an author publication search of all authors who contributed 
to the potentially relevant studies [25]. Following review of a total of seven papers, only two studies 
met the inclusion criteria and underwent data extraction (Figure 1.3) [26,27]. The author of one 
study was contacted for clarification of data, but did not respond within the allocated timeframe and 
was consequently excluded from analysis [28]. A list of studies excluded after critical appraisal and 
their reasons for exclusion is presented in Table 1.1. 
 
Table 1.1: Excluded studies and reasons for exclusion. 
Study [reference] Reason/s for exclusion 
Chu et al.[29] Detected lesions were not limited to oral cavity and oropharynx, and there was 
insufficient information to determine the sensitivity, specificity, PPV and NPV for 
the subset of data relating to only the oral cavity and oropharynx. 
Irjala et al.[7] Insufficient information to determine sensitivity, specificity, PPV, NPV. 
Piazza et al.[24] Is not the most current primary report of the study. 
Nguyen et al.[28] Detected lesions were not limited to oral cavity and oropharynx, and there was 
insufficient information to determine the sensitivity, specificity, PPV and NPV for 
the subset of data relating to only the oral cavity and oropharynx. 
Yang et al.[25] No details regarding the efficacy of WL. 
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Figure 1.3. Flow diagram of the literature search strategy and study selection process. 
 
 
1.4.1 Descriptions of studies 
The two included papers were cohort studies – with one being prospective while the other, 
retrospective [26,27] The prospective study by Piazza et al. commenced in April 2007 at the 
Department of Otorhinolaryngology – Head and Neck Surgery of the University of Brescia, Italy, 
until completion in January 2010 [26] In contrast, Yang et al. conducted a retrospective study at the 
Department of Otolaryngology – Head and Neck Surgery of Chang Gung Memorial Hospital, 
Keelung City, Taiwan, between April 2009 and August 2011 [27] All patients in the two studies 
underwent WL examination before NBI. While Piazza et al. used a transnasal flexible 
videoendoscope (ENF-VQ-High Resolution) to evaluate the upper aerodigestive tract (UADT) 
under local anaesthesia, rigid endoscopes (transoral 0° and 70°) with a high definition television 
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from EMBASE 
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(n=26) 
Total studies excluded (n=106) 
Duplicated citations (n=51) 
Irrelevant (n=55) 
Full record of potentially relevant studies retrieved to be assessed for eligibility 
(n=5) 
Publications meeting inclusion criteria and critically appraised 
(n=2) 
Additional studies retrieved (n=2) 
Study identified from searching 
reference lists (n=1) 
Study identified from author 
publication search (n=1) 
Total number of studies to be assessed for eligibility 
(n=7) 
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(HDTV) camera connected to a CLV-180B light source on an Evis Exera II system were used to 
examine the oral cavity and oropharynx. Yang et al. utilised flexible endoscopes (ENF-V2, Type 
VQ and Type VT) with a CLV-160B light source connected to a CV-160B central videosystem to 
examine just the oral cavity. Both studies compared NBI with WL, and reported the efficacy for 
each light for aiding the detection of dysplasia and cancer in terms of sensitivity, specificity, PPV, 
NPV and accuracy [26,27] 
 
1.4.2 Review participants 
All patients from the included studies had either known OPML, OSCC and/or OPSCC, or were at 
risk of having these lesions [26,27] Piazza et al. examined a total of 444 treated and untreated 
patients (369 males and 75 females aged between 27 and 86 years of age, mean age of 63 years) 
with known UADT squamous cell carcinoma (SCC); however, only 97 patients had either treated or 
untreated OSCC or OPSCC and had their oral cavity and oropharynx evaluated [26] Yang et al. 
included 317 patients (274 males and 43 females between the ages of 22 and 82, mean age of 52 
years) with only histopathologically diagnosed hyperkeratosis, parakeratosis, squamous 
hyperplasia, dysplasia, CIS, or OSCC. Other types of white lesions, and interestingly, those with 
other OPMLs such as discoid lupus erythematosus and lichen planus, were excluded from the latter 
study (Table 1.2) [27]   
 
1.4.3 Quality of studies 
The two included studies had an overall low risk of bias, with an overall low concern regarding 
applicability of the studies to this review. All patients in both studies were examined with WL and 
NBI, and lesions were interpreted using specific criteria associated for each study [26,27]. Although 
blinding was not described in one study [26], this is unlikely to affect the outcome. All patients in 
one study received biopsies [27], whereas the other study only biopsied positive lesions [26]. 
However, negative lesions were reviewed for a minimum of six months in order to determine the 
true negatives and thus the risk of bias is considered to be low [26]. All patients were included in 
the analysis of each study [26,27]. 
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1.4.4 Effects of intervention 
1.4.4.1 Efficacy of NBI in comparison to WL 
The sensitivity, specificity, PPV, NPV and accuracy for detecting dysplasia or worse in the oral and 
oropharyngeal cohort in the study conducted by Piazza et al. was 96%, 98%, 96%, 98% and 97% 
respectively for both NBI alone and NBI with HDTV, whereas it was 56%, 100%, 100%, 87% and 
89% respectively for WL with HDTV [26]. In contrast, Yang et al. reported sensitivity, specificity, 
PPV, NPV, accuracy, false positive percentage and false negative percentage of 96.30%, 60.08%, 
33.12%, 98.75%, 66.25%, 39.92 and 3.70% respectively for WL, and 87.04%, 93.54%, 73.44%, 
97.23%, 92.43%, 6.46% and 12.96% respectively for NBI. When WL classification was combined 
with NBI classification, the false negative percentage decreased to 0% and both the sensitivity and 
NPV improved to 100%; however, the specificity, PPV, accuracy and false positive percentage was 
60.08%, 33.96% and 66.88% respectively (Table 1.2). There was a significant difference with using 
WL classification to NBI classification (p<0.001), but not to the combined WL and NBI 
classification (p=0.564). Use of NBI classification was significantly different to the combined WL 
and NBI classification (p<0.001) [27]. 
1.4.4.2 Criteria for determining the presence of disease 
For one study, the presence of a ‘well-demarcated brownish area with thick dark spots and/or 
winding vessels’ under NBI was used to indicate the presence of disease; however, the authors did 
not comment on the effectiveness of using this criteria, nor did they define a criteria for WL [26]. In 
contrast, Yang et al. categorised white lesions as either homogenous or non-homogenous under WL, 
and into four categories (types I to IV) based on the IPCL pattern under NBI. Non-homogenous 
lesions and those with either types III (twisted, elongated, or meandering IPCLs) or IV (IPCL 
destruction) IPCL patterns had a significantly increased risk of having high grade dysplasia (HGD), 
CIS or OSCC (odds ratio (OR)=39.12, 95% CI=9.33-6.10 and OR=97.16, 95% CI=38.19-247.21 
respectively) [27]. 
1.4.4.3 Correlations between IPCL patterns and diagnoses 
Only one study assessed the specific type of IPCL pattern in lesions [27]. In this study, the authors 
defined four types of IPCL patterns: type I as having regular and organised IPCLs, type II as having 
tortuous or dilated IPCLs, type III as having twisted, elongated, or meandering IPCLs, and type IV 
if IPCL destruction was present. Of the 253 lesions with types I or II IPCL patterns, only 7 (2.77%) 
had HGD, CIS or OSCC; the rest did not have HGD, CIS or OSCC. Of the 64 cases with types III  
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Table 1.2: Characteristics of included studies. 
Study  Type of study Participants Light 
Results 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Accuracy 
(%) 
False 
positive % 
False 
negative % 
Piazza 
et 
al.[26] 
Not 
randomised, 
not blinded 
prospective 
cohort study 
444 patients with 
untreated or treated 
known UADT SCC 
 - 369 males 
 - 75 females 
 - mean age 64 
years 
 - range 27-86 years 
 
Of the 444, 97 
patients had 
untreated or treated 
known OSCC or 
OPSCC (details for 
this cohort only) 
WL 
+HDTV 
56 100 100 87 89 - - 
NBI 96 98 96 98 97 - - 
NBI 
+HDTV 
96 98 96 98 97 - - 
Yang 
et 
al.[27] 
Retrospective 
cohort study 
with blinding 
to the sources 
of data 
317 consecutive 
patients with 
biopsy-confirmed 
hyperkeratosis, 
parakeratosis, 
squamous 
hyperplasia, 
dysplasia, CIS, or 
OSCC. 
WL 96.30 60.08 33.12 98.75 66.25 39.92 3.70 
NBI 87.04 93.54 73.44 97.23 92.43 6.46 12.96 
WL+NBI 100 60.08 33.96 100 66.88 39.92 0 
UADT = Upper aerodigestive tract; SCC = squamous cell carcinoma; OSCC = oral squamous cell carcinoma; OPSCC = oropharyngeal squamous cell carcinoma;  
CIS = carcinoma in situ; WL = white light; NBI = narrow band imaging; HDTV = high definition television.
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or IV IPCL patterns, 47 (73.44%) had HGD, CIS or OSCC whereas the remaining 17 cases 
(26.56%) did not have any of these diagnoses [27]. 
1.4.4.4 Advantages of using NBI in the oral cavity and oropharynx 
NBI improved the visualisation of lesions [26,27], thereby enhancing the ability to stage tumours, 
assess margins, and detect synchronous, metachronous and recurrent lesions. These advantages over 
conventional WL also allowed NBI to influence treatment [26].  
1.4.4.5 Limitations of NBI in the oral cavity and oropharynx 
Both studies reported that there was a steep learning curve associated with using NBI, and that 
inexperience influenced how lesions and their microvasculature pattern were interpreted [26,27]. 
 
 
1.5 Discussion 
Early detection of malignant and potentially malignant mucosal lesions in the head and neck is 
critical for improving patient prognosis as treatment is less invasive [24]. Although use of WL in 
the oral cavity has relatively high sensitivity and specificity [30], early lesions may be present in 
clinically normal mucosa and can therefore be easily missed with WL examination [31]. Many 
visualisation adjuncts on the market aim to improve the detection rates of dysplasia and cancer; 
however, most have issues with differentiating benign lesions from dysplasia and neoplasia [32]. 
The results of this review demonstrate that NBI has a higher diagnostic accuracy than WL for 
aiding the detection of OPML, OSCC and/or OPSCC. Both studies reported consistently high 
values across the board for NBI [26,27],
 
which suggests that the overall false positive and false 
negative rates tend to be low with the use of NBI. However, it is still unclear whether or not NBI 
has better sensitivity, specificity, PPV and NPV than WL based on these two studies alone [26,27]. 
In one study, NBI alone and NBI with HDTV had higher sensitivity and NPV but lower specificity 
and PPV than WL with HDTV [26]. This was the reverse with the other study, with higher 
specificity and PPV but lower sensitivity and NPV reported for NBI in comparison to WL [27]. 
Combining WL and NBI classifications did not necessarily result in improved diagnostic accuracy 
across the board, as Yang et al. reported that while sensitivity and NPV improved, specificity, PPV 
and accuracy dropped to almost the same, if not the same, as the WL values [27]. Instead, use of 
NBI classification alone was significantly better than using WL or combined WL and NBI 
classifications for aiding the detection of HGD or worse [27]. 
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Several other papers have also reported the effectiveness of NBI over WL for aiding the detection 
of dysplasia and cancer [23,25]. The only published meta-analysis of studies assessing the 
diagnostic accuracy of NBI in the oral cavity and/or oropharynx calculated 92% sensitivity, 95% 
specificity, 25.11 positive likelihood ratio (PLR) and 0.09 negative likelihood ratio (NLR) [23]. In 
comparison, WL had 50% sensitivity, 100% specificity, 21.10 PLR and 0.52 NLR [23]. Based on 
the information provided, one retrospective and two prospective studies were included for this 
meta-analysis [24,33], and of these three studies, only one met the inclusion criteria for the current 
review [24,34]. The validity of this meta-analysis must be questioned as one of the included 
prospective papers is an abstract that appears to be an earlier report of the other included 
prospective paper [24,34]. Nonetheless, other studies report similar values of efficacy, with a recent 
study investigating the use of NBI for aiding the detection of OSCC in chronic oral ulcers persisting 
for longer than three weeks noting 93.75% sensitivity, 91.49% specificity, 78.95% PPV, 97.73% 
NPV and 92.06% accuracy [25]. It is clear that NBI has very high accuracy for detecting potentially 
malignant and malignant mucosal lesions in the oral cavity and oropharynx. Other studies that have 
used NBI in the head and neck and have found oral and oropharyngeal lesions have also reported 
similar values of efficacy for NBI [28,29]. 
A prospective study by Nguyen et al. used WL, autofluorescence and NBI to examine the oral 
cavity, hypopharynx, larynx and bronchus of 73 patients with HNSCC, SCC of unknown primary 
origin, or previously treated HNSCC patients who were thought to have recurrent disease [28]. Of 
these, 25 patients had a primary tumour site in the oral cavity. The authors reported 96% sensitivity 
and 79% specificity for moderate dysplasia or worse by NBI, whereas the sensitivity and specificity 
for autofluorescence was 96% and 26% respectively, and for WL it was 37.5% and 95% 
respectively. Detection of significant dysplasia or worse was therefore significantly better with NBI 
than with WL, and both NBI and WL had less false negative findings than autofluorescence. The 
use of autofluorescence and NBI significantly affected the immediate management of three oral 
cases – namely, they assisted with mapping the surgical margins. This finding is supported by not 
only Piazza et al., but also other studies that have reported the value of NBI in determining the 
resection margins of OPMLs and OSCCs [21,35,36]. By using NBI prior to excision, the true extent 
of a lesion can be determined such that complete resection is possible [35]. NBI also influenced the 
long-term follow-up of one oral lesion with confirmed moderate dysplasia that had persistent NBI 
changes [28]. 
Knowledge of the IPCL pattern can influence the subsequent course of care because the likelihood 
of more serious pathology being present increases with each stepwise increase in the IPCL pattern 
type [21,37]. As shown in the study conducted by Yang et al., the IPCL pattern shown by NBI 
16 
 
correlates with the pathological severity of oral leukoplakia better than using clinical morphological 
features of leukoplakia [27]. In non-neoplastic and non-inflammatory lesions, there are no 
irregularities in IPCL; however, once inflammation occurs, IPCLs will proliferate, elongate and 
dilate slightly. Furthermore, with dysplastic lesions, the IPCLs not only increase in density, dilation 
and calibre, but also extend upwards, proliferate and branch irregularly in accordance with the 
degree of dysplasia. The lesion becomes thicker due to the increased microvascular density (MVD) 
and will eventually result in subepithelial invasion and destruction of IPCLs if left untreated. By 
this stage, the lesion becomes an invasive SCC. As there is a significant correlation between the 
thickness of intraepithelial lesions, MVD and subepithelial invasion, the detection of malignant and 
potentially malignant mucosal lesions at an early stage is very important [13]. 
The idea of early detection is supported by a study involving 154 patients with newly diagnosed 
leukoplakia. In this study, the authors reported 16.67%, 92.31% and 100.00% frequencies of 
dysplasia in lesions with IPCL types I, II and III respectively. All lesions with IPCL type IV were 
histopathologically confirmed as SCC, and this suggests that IPCL type IV could be pathognomonic 
of OSCC [38]. A different study which used three microvascular patterns very similar to the types 
II, III and IV IPCL patterns outlined in Takano’s IPCL classification for oral mucosa confirmed 
these findings [21,39]. In this study, the IPCL types II and III equivalents were associated with 
premalignant and carcinomatous lesions, whereas the IPCL type IV equivalent was only present in 
OSCC [39]. The sensitivity, specificity, PPV, NPV, accuracy and OR for detecting HGD, CIS and 
invasive carcinoma using IPCL types III and IV as the criteria for differentiating neoplastic mucosa 
from normal mucosa were generally very high at 84.62%, 94.56%, 74.32%, 97.06%, 93.0% and 
95.53 (95% CI: 42.19-216.29) respectively [38]. Consequently, lesions with IPCL types II, III or IV 
under NBI illumination should be biopsied [37]. 
A retrospective study also found a significant association between types III and IV IPCL patterns 
and the presence of OSCC in non-healing ulcers, with the sensitivity, specificity, PPV, NPV and 
accuracy for using types III and IV IPCL patterns as the diagnostic criteria at 93.75%, 91.49%, 
78.95%, 97.73% and 92.06% respectively [25]. While a chronic ulcer in itself is not considered an 
OPML by the World Health Organization [40], it can be a sign of malignancy [25]. This study 
further demonstrates the diagnostic utility of intraepithelial microvascular morphology for 
determining the presence of neoplasia. 
While Yang et al. utilised IPCL patterns to identify the presence of disease under NBI [27], Piazza 
et al. used a more basic criteria and instead looked for the presence of a ‘well-demarcated brownish 
area with thick dark spots and/or winding vessels’ [26]. The scattered brown dots represent the 
superficial microvessels, whereas the intervascular brownish epithelium may be due to increased 
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intraepithelial cell density or the inherent changes in intraepithelial cells that occurs during 
malignant transformation [41]. Use of this criterion for detecting HGD, CIS or SCC is less effective 
than by using the IPCL patterns [33]. Furthermore, recent research has shown that the prevalence of 
brownish spots is not consistent in all areas of the head and neck [42]. Variations in the epithelium 
such as the degree of keratinisation and thickness, and the presence of lymphoid tissue can affect 
visualisation of the subepithelial microvasculature architecture and IPCLs [42]. 
For NBI to be effective, light must be able to penetrate the epithelium. The oral cavity has several 
different types of epithelium depending on the location, and Lin et al. investigated the effect this 
had on the appearance of brownish spots [42]. In their study, 125 patients with early or occult 
mucosal head and neck cancer were examined and then split into two groups according to the 
presence or absence of brownish spots. There was a significantly higher prevalence of brownish 
spots (OR=76.45) in areas lined with non-keratinised thin stratified squamous epithelium such as 
the floor of mouth, ventral tongue and soft palate, than in areas lined with thicker (i.e. greater than 
500 µm) or keratinised epithelium [42]. In contrast, another study reported that visualisation of the 
microvasculature is not affected by the degree of keratinisation in normal mucosa, unless there is 
hyperkeratosis associated with leukoplakia [38]. 
Several studies have reported impaired visualisation of the microvascular network in the presence 
of leukoplakia [21,29,38]; however, Yang et al., reported that it is still possible to observe the 
underlying vasculature under thin homogenous leukoplakia [37]. In Yang’s study, only type I IPCL 
pattern was seen in thin homogenous leukoplakia, and the majority were histopathologically 
diagnosed with squamous hyperplasia. Conversely, visibility of the microvasculature was vague, 
blurry or completely obstructed where there was thick homogenous leukoplakia. Instead, 
examination of the mucosa surrounding the lesion was necessary to determine the most likely IPCL 
pattern for the lesion. Interestingly, 75.20% of thick homogenous leukoplakia were surrounded by 
IPCL type I, and of these, 27.66% had dysplasia. Therefore, the IPCL pattern of the surrounding 
tissue may not be indicative of the actual pattern under the hyperkeratosis. The fact that types II and 
III IPCL patterns could be observed around thick homogenous leukoplakia but not under thin 
homogenous leukoplakia, however, suggests that the amount of hyperkeratinisation may correlate to 
the degree of dysplasia [37]. Suspicion should also be increased if non-homogenous leukoplakia is 
present, as these lesions are more likely to have high grade dysplasia, CIS or invasive carcinoma 
than homogenous leukoplakia [33,38]. Visualisation of the underlying microvasculature may also 
be impaired in ulcerated lesions due to the presence of fibrin slough or pseudomembrane [25]. 
Although there are still physiological and anatomical issues that affect the visualisation of the 
superficial microvasculature [38,42], NBI is safe, fast and well-tolerated [25]. The main limiting 
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factor is the steep learning curve associated within the first six months of using the NBI system; 
however, once the clinician has passed this phase, using and interpreting results becomes easier 
[24,27]. All studies were conducted by specialists in a specialist setting, and thus the results cannot 
be generalised to general practitioners or the general population. It is important to note that the use 
of NBI is not intended for general dental or medical practitioners due to the cost involved in NBI 
system setup and the level of training required for effective use. Nonetheless, data collected for any 
study while the screening clinician was in the learning phase may have skewed results. 
 
 
1.6 Conclusions 
Existing data suggests that NBI has great potential to not only accurately aid the detection and real-
time assessment of new and existing OPML, OSCC and OPSCC, but also influence their treatment. 
Although data regarding the efficacy of NBI for aiding the detection of OPML, OSCC and OPSCC 
is still limited, with the majority of published papers being case reports [35,36], retrospective 
studies [25,27,33,37-39], and a few prospective studies [21,24,29], there is building evidence to 
suggest its beneficial use over WL alone for detecting and monitoring mucosal lesions in the oral 
cavity and oropharynx. There is however currently no published prospective study that has 
specifically assessed the use of NBI for the detection of OPMLs, let alone any randomised 
controlled trial to provide a higher level of evidence. More trials, particularly randomised controlled 
trials in secondary or tertiary settings, are required to evaluate the efficacy of NBI for detecting both 
potentially malignant and malignant lesions.  
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1.9 Hypothesis and Aims 
The hypothesis for this thesis is that NBI will have a high degree of efficacy for aiding the detection 
of OPMLs, and can be used to delineate areas of healthy from diseased tissue. 
The primary aim of the first experimental chapter is to evaluate the use of NBI for the clinical 
detection OPMDs. A secondary aim of the first chapter is to also determine if there are any 
associations between the clinical appearance of lesions under NBI and histology. The second 
experimental chapter aims to correlate the mRNA and microRNA gene expression profiles at 
primary tumour margins defined by NBI and WL. 
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2.1 Abstract 
Objective: To determine the clinical diagnostic accuracy of Narrow Band Imaging™ for the 
detection of oral potentially malignant disorders in a prospective series of patients. 
Materials and Methods: New and existing patients referred to an oral medicine and pathology 
specialist clinic for assessment of at least one white, red, or red-white oral lesion underwent 
conventional oral examination, followed by examination with the white light mode then narrow 
band imaging mode of a Narrow Band Imaging system. The clinical presentation, microvascular 
architecture and relevant histopathology of all lesions were recorded. 
Results: A total of 272 lesions from 95 patients were observed. The sensitivity, specificity, positive 
predictive value, negative predictive value and accuracy for the detection of oral potentially 
malignant disorders or worse by narrow band imaging were 100%, 74.63%, 92.38%, 100% and 
93.77% respectively when compared with conventional oral examination.  Narrow Band Imaging 
aided the detection of 24 lesions undetected by conventional oral examination and 13 lesions 
undetected by white light endoscopy. 
Conclusion: Narrow Band Imaging demonstrates great utility as a visualisation adjunct for 
detecting and monitoring oral potentially malignant diseases, particularly lesions not identified by 
conventional oral examination or white light examination alone. 
 
 
 
Keywords: narrow band imaging; oral potentially malignant disorders; oral potentially malignant 
lesions; oral cancer; detection; sensitivity and specificity 
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2.2 Introduction 
Oral cancer ranks as the eighth and thirteenth most common malignancies in the world for males 
and females respectively [2]. The five year survival rate still remains at around 50% despite 
advances in treatment over the past 30 years, as over 60% of patients present with stage III or IV 
oral cancer [2,43]. Early detection and diagnosis of oral cancer improves prognosis as the often 
painful, invasive and disfiguring treatment for late-stage cancer is associated with high morbidity 
and mortality [2,10-13,43]. However, early detection of oral cancer is hampered by the fact that 
many early-stage cancers are relatively asymptomatic and difficult to detect using standard white 
light (WL) inspection [12]. Therefore, use of a visualisation adjunct that enhances the subtle 
epithelial changes occurring in potentially malignant and malignant lesions may potentially improve 
patient outcomes. 
Narrow Band Imaging™ (NBI; Olympus Medical Systems Corporation, Tokyo, Japan) is an 
endoscopic technique that enhances the mucosal surface texture and mucosal and submucosal 
vascular morphology [15]. Two 30 nm wide bands of blue and green light are filtered from white 
light and are emitted simultaneously in NBI mode. The capillary bed and intrapapillary capillary 
loop (IPCL) pattern appears brown due to the blue light centred at 415 nm, as this wavelength 
corresponds to the peak absorption spectrum of haemoglobin. Thicker blood vessels in the deeper 
mucosa and submucosa appear cyan due to the green light centred at 540 nm [15-18]. As 
angiogenesis is associated with potentially malignant and malignant lesions, the ability for NBI to 
enhance the microvascular architecture enables clinicians to delineate diseased tissue from normal 
mucosa [13]. 
Use of the IPCL classification for oral mucosa can assist clinicians in differentiating high risk 
lesions from benign [21,38]. This classification consists of four types of IPCL patterns, with the 
most advanced IPCL pattern designated to the lesion if more than one pattern is present. Type I 
IPCL pattern is typically associated with normal mucosa, and appears as either scattered brown dots 
when the capillary loops are perpendicular to the surface or waved lines when the loops are parallel. 
Dilated loops that cross each other are classified as type II. Type III IPCL pattern is characterised 
by elongated and meandering loops, whereas type IV is distinguished by large vessels, IPCL pattern 
destruction and angiogenesis [21]. Lesions with types III or IV IPCL patterns are at higher risk of 
having high grade dysplasia, carcinoma in situ, or invasive carcinoma [33]. 
Although the use of NBI in the oral cavity has only been a fairly recent development, existing 
literature suggests that it may be a valuable adjunct for visualising potentially malignant and 
malignant oral lesions [44]. To date, there are only a few studies evaluating the use of NBI in oral 
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cavity – all of which have primarily focussed on its ability to enhance dysplasia and oral squamous 
cell carcinoma (OSCC) [24,28,29]. The issue with many devices marketed to aid the detection of 
neoplastic lesions is their ability to differentiate benign inflammatory lesions from potentially 
malignant and malignant lesions [32,45-47]. There is currently no published study to our knowledge 
that prospectively evaluates the use of NBI for detecting oral potentially malignant disorders 
(OPMDs), and how it compares to both traditional conventional oral examination (COE) and WL 
endoscopy (referred to as ‘WL’ hereafter). The primary aim of this prospective clinical study is to 
compare the efficacy of NBI for the clinical detection of OPMDs to the current gold standard, COE. 
To a lesser extent, the study also aimed to determine if there are any associations between the 
clinical appearance of lesions under NBI and histology.   
 
 
2.3 Materials and Methods 
2.3.1 Study population 
New and existing patients at a single site oral medicine and pathology specialist referral practice in 
Brisbane, Australia [48] were invited to participate in the study. The clinic is serviced by a single 
oral medicine specialist (CSF) who undertook initial and review clinical examinations for all 
patients. Over a 5 month period from April to August 2013, patients presenting for examination of 
undiagnosed oral mucosal lesions were recruited into the study. In addition, patients from an invited 
sample of 317 with a previously diagnosed OPMD [45,49,50] who consented to have their existing 
mucosal lesions examined with NBI were also included (Figure 2.1). The inclusion criteria for this 
study were patients at least 18 years of age presenting with at least one white, red, or red-white 
lesion. Lesions with an ulcerative component were included.  
Patients were given both verbal and written explanations about the study at the beginning of their 
appointment. Participation in the study was voluntary and written informed consent was obtained 
from all patients before any data was collected. This study was designed in accordance with 
STARD guidelines [51], followed the principles outlined in the Declaration of Helsinki (2008), and 
was covered under ethics approval HREC/QRBW/10/336. 
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2.3.2 Examination 
Age, gender, smoking, alcohol and mouthwash use history of all patients enrolled in the study were 
recorded. All patients underwent a COE conducted by an Oral Medicine Specialist (CSF) equipped 
with a light emitting diode (LED) white light (Zeon Discovery™ LED Headlight; Orascoptic, Kerr 
Corporation, Middleton, WI, USA) and 2.5x magnification loupes. White light with loupes 
magnification was used as it is now considered the gold standard for examining patients for oral 
mucosal lesions [45,47]. The examiner was blinded to all patient notes including previous 
histopathological reports, and lesions detected by COE in existing patients were classified as an 
‘existing’ lesion. Patients were then examined with the NBI system in the conventional sequence of 
WL mode first followed by NBI mode. The Evis Exera III NBI system was equipped with an 
Olympus 0° rigid endoscope attached to a CH-S190-XZ-E camerahead, Evis Exera III Xenon Light 
Source CLV-190, Evis Exera III Video System Centre CV-190 and an IMH-20 high definition 
central video system (Olympus Medical Systems). Images were viewed on a high definition LCD 
monitor (OEV261H, Olympus Medical Systems). The camerahead not only provided 1.5 x digital 
magnification during both the WL and NBI examinations, but also allowed for switching between 
WL and NBI modalities. Lesions not detected by COE but later with WL and/or NBI were 
classified as a ‘new’ lesion. 
The location, size and appearance of lesions under each light were recorded. For COE and WL, the 
colour (white, red or red-white), clinical appearance (homogeneous, non-homogeneous, lichenoid or 
other), ease of visibility (poor or excellent), border distinctness (diffuse or sharp) and clinical 
provisional diagnosis of each lesion were noted. Whether WL enhanced visibility more than COE 
or changed the clinical provisional diagnosis for each lesion was also recorded. 
Lesion features observed for lesions under NBI included surface texture (keratotic, erosive, neither 
or both) and visibility of IPCLs within the lesion borders. IPCL visibility was scored as ‘not at all’ 
if the IPCLs were not visible across the whole lesion; ‘moderate’ if the IPCLs were only visible 
around areas of keratosis found within the confines of the lesion borders; ‘high’ if the IPCLs were 
visible around and under some areas of keratosis found within the confines of the lesion borders; 
and ‘complete’ when there was excellent visibility of IPCLs across the whole lesion. Lesions were 
also classified using Takano’s IPCL classification of oral mucosa [21], with the additional category 
of ‘type 0’ for lesions where IPCLs were not visible within the confines of the lesion’s borders 
(Figure 2.2). The most advanced IPCL pattern detected was designated the lesion IPCL type. All 
lesions were given an updated clinical provisional diagnosis after NBI examination.  
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A video recording of the WL and NBI examination was made so that a general dental practitioner 
(ANV) could review and score the NBI images while blinded to the patient examinations. Unlike 
the oral medicine specialist who had extensive knowledge on oral pathology and one year 
experience with using NBI, the second examiner only had basic training on oral mucosal pathology 
and very limited expertise with interpreting NBI recordings. A general dental practitioner was 
chosen to review NBI videos in order to determine whether or not someone with more basic training 
could accurately interpret the patterns. Where there were discrepancies in designated lesion IPCL 
patterns, video recordings were reviewed together before settling on a final IPCL pattern. 
 
2.3.3 Biopsy and histopathology 
A biopsy was undertaken of any lesion considered clinically suspicious or sinister for dysplasia or 
worse by any imaging modality. For lesions biopsied based on NBI findings, areas of more 
progressed IPCL patterns, specifically types III or IV, were chosen in preference to areas with only 
minor changes in the degree of dilation, meandering, tortousity and calibre of IPCLs. This is in 
accordance with the standard practice to biopsy the most sinister part of lesions suspicious of 
having dysplasia [52]. If required, biopsies were performed by the screening clinician at a two week 
review appointment, provided that the lesion was still present. Biopsy specimens were fixed in 
formalin, blocked in paraffin, and stained with haematoxylin and eosin before being assessed by a 
head and neck pathologist not involved in the clinical aspect of the study. Histopathological reports 
were compared with the clinical provisional diagnoses.  
 
2.3.4 Statistical analysis 
Any patient with no visible red, white, or red-white oral mucosal lesion at the time of examination 
was excluded from statistical analysis. For analysis, lesion location was grouped in accordance with 
the International Statistical Classification of Diseases and Related Health Problems 10
th
 Revision 
(ICD-10) Version for 2010 (http://apps.who.int/classifications/icd10/browse/2010/en#/C00-C97). 
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 
their corresponding 95% confidence intervals were calculated using MedCalc 
(http://www.medcalc.org/calc/diagnostic_test.php). When calculating clinical efficacy using another 
light as the gold standard, a clinical provisional diagnosis of either an OPMD as defined by the 
World Health Organisation (WHO) [40]  or worse was considered positive for the presence of 
disease for all light examinations. For analyses using histopathology results as the gold standard, 
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the presence of any degree of dysplasia (i.e. mild, moderate or severe with or without another 
condition) was considered a positive result [53]. These categorisations were also used to determine 
if there was a relationship between IPCL pattern and the presence of OPMD or worse. 
For the majority of statistical analyses assessing relationships between diagnoses and clinical 
variables, diagnoses were categorised into ‘homogeneous leukoplakia/keratosis’, ‘non-
homogeneous leukoplakia/suspicious for malignancy’, ‘lesions with lichenoid features’ and ‘other’ 
as previously described [45]. Use of these four categories has previously been shown to have a 
significant association with oral epithelial dysplasia (p<3.010
-19
) [54]. The same calculations were 
repeated using a simpler classification system consisting of only two categories: ‘no disease’ and 
‘disease’. ‘Disease’ was any OPMD diagnosis as defined by WHO [40], and ‘no disease’ was all 
other diagnoses. Calculations were performed using R Commander (version 2.15.3; http://www.r-
project.org). Dichotomous variables were compared using Fisher’s exact test with a significant 
statistical difference considered at p<0.05.
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Figure 2.1. Overview of examination procedure and summary of findings. 
COE = conventional oral examination; WL = white light modality; NBI = narrow band imaging modality. 
Lesions were categorised into the four groups as described by us in previous work [45]. 
‘Homogeneous leukoplakia/keratosis’ included lesions clinically diagnosed as homogeneous leukoplakia or any form of keratosis. 
‘Non-homogeneous leukoplakia/suspicious for malignancy’ included lesions clinically diagnosed as non-homogeneous leukoplakia, actinic cheilitis, or was clinically suspicious for 
dysplasia or malignancy. 
‘Lesions with lichenoid features’ included lesions clinically diagnosed with oral lichen planus, or oral lichenoid tissue reaction. This category did not include lesions clinically 
suspicious for lichenoid dysplasia as this was classed in the ‘Non-homogeneous leukoplakia/suspicious for malignancy’ category. 
‘Other’ included vascular lesions, scar tissue, benign lumps, traumatic ulcers and lesions clinically diagnosed as candidosis including chronic hyperplastic candidosis.
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Figure 2.2. Comparison between WL and NBI images. 
(a) WL image of leukoplakia on gingiva. (b) NBI image of leukoplakia on gingiva. IPCL type 0 pattern as IPCL pattern 
cannot be seen within the keratotic area. (c) WL image of leukoplakia on hard palate. (d) NBI image of leukoplakia on 
hard palate. IPCL type 0 pattern as IPCL pattern cannot be seen within the keratotic area. (e) WL image of leukoplakia 
on buccal mucosa. (f) NBI image of leukoplakia on buccal mucosa. Type I IPCL pattern can be seen where there is thin 
or no keratosis. Red arrows mark where images g and f are located. (g) Magnification from area in image (f) where the 
type I pattern consists of regular brown dots. (h) Magnification from area in image (f) where the type I pattern consists 
of waved lines. (i) WL image of ulcerated lesion on buccal mucosa in a patient with oral lichen planus. (j) NBI image of 
ulcerated lesion on buccal mucosa in a patient with oral lichen planus. Type II IPCL pattern can be seen surrounding the 
fibrin centre, which appears pink on NBI. (k) WL image of lichenoid lesion on lateral tongue. (l) NBI image of 
lichenoid lesion on lateral tongue. Type II IPCL pattern can be seen surrounding the fibrin centre where there is less 
keratosis. (m) WL image of non-homogeneous leukoplakia on lateral tongue extending into floor of mouth. (n) NBI 
image of non-homogeneous leukoplakia on lateral tongue extending into floor of mouth. Type III IPCL pattern can be 
seen where there is thin or no keratosis. Red arrows mark where images o and p are located. (o) Magnification from 
area in image (n) demonstrating the elongated and meandering characteristics of type III IPCL pattern. (p) 
Magnification from area in image (n) demonstrating the elongated and meandering characteristics of type III IPCL 
pattern. (q) WL image of squamous cell carcinoma on soft palate. (r) NBI image of squamous cell carcinoma on soft 
palate. Several types of IPCL patterns can be seen; however, type IV IPCL pattern located by the red arrow was the 
worst pattern present and therefore the pattern assigned to the lesion. (s) Magnification from area in image (r) with type 
IV IPCL pattern. Angiogenesis and IPCL pattern destruction present. Refer to Appendix II for larger and higher 
resolution versions of these images. 
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2.4 Results 
Between April 2013 and August 2013 inclusive, a total of 96 patients (10 new, 86 review) were 
examined by COE, WL and NBI consecutively. One patient did not have any lesion and was 
excluded from analysis (Fig. 1). Of the 95 patients with lesions, 43 (45.26%) were male and 52 
(54.74%) were female. Demographic information of patients are summarised in Table 2.1. 
 
Table 2.1: Demographic information of patients examined (total n=95). 
Gender Male (n=43) Female (n=52) 
New Patients n (%) 3 (6.98) 6 (11.54) 
Existing Patients n (%) 40 (93.02) 46 (88.46) 
Age Years (mean ± SD) 58.58 ± 9.42 62.09 ± 11.12 
Age range (years) 28-76 31-84 
Smoking Historya n (%) 30 (69.77) 24 (46.15) 
Pack Years (mean ±SEM) 30.71  ± 4.63 18.67 ± 3.12 
Alcohol Consumption Historya n (%) 37 (86.05) 44 (84.62) 
Smoking & Alcohol Historya n (%) 27 (62.79) 24 (46.15) 
SD = Standard deviation; SEM = Standard error of the mean 
a Past and current consumers included 
 
From 95 patients, a total of 272 lesions were observed by the end of the study period (Figure 2.1). 
Most lesions were located on the buccal mucosa (41.54%) and tongue (27.21%) (Table 2.2). The 
majority of lesions (87.13%) had previously been examined before commencement of this study, 
and 27.21% had a pre-existing histopathological diagnosis (Table 2.3). Whilst a few pathologists 
were involved in assessing biopsies [53], the large majority were assessed and reported by one main 
pathologist. For lesions that had a previous biopsy, there was a significant association between COE 
provisional diagnosis and the previous biopsy result (p<0.01). 
 
Table 2.2: Location of lesions (n=272). 
Location Number of lesions n (%) 
Buccal mucosaa 114 (41.91) 
Tongue 74 (27.21) 
Gingiva  34 (12.50) 
Lipb 19 (6.99) 
Palatec 18 (6.62) 
Floor of mouth 13 (4.78) 
a Includes 1 lesion on the retromolar pad 
b Lip includes lip external and labial mucosa 
c Palate includes hard and soft palate 
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Table 2.3: Overview of lesion biopsies (n=272). 
Lesion type 
New 
n (%) 
Existing 
n (%) 
Lesions found by end of examination 39 (13.24) 233 (85.66) 
Lesions with a previous biopsy before commencement of study  4 (1.47) 70 (25.74) 
Lesions with multiple previous biopsies N/A 20 (7.35) 
Last previous biopsy type - incisional N/A 43 (15.81) 
Last previous biopsy type - excisional N/A 31 (11.40) 
New biopsy taken during study 9 (3.31) 20 (7.35) 
N/A = Not applicable 
 
There was minimal difference between COE and WL for observing colour, clinical appearance, 
visibility and border distinctness of lesions. Both COE and WL clinical provisional diagnoses were 
significantly associated with colour (p<0.01) and border distinctness (p<0.01). Despite very similar 
findings to COE, WL enhanced the overall visibility of 99.3% lesions visualised by COE due to its 
stronger magnification properties, and aided the detection of 11 lesions missed by COE. 
The inclusion of NBI in the examination not only provided the clinician a magnified view to assess 
for changes in mucosal surface texture, but also better contrast of the microvascular morphology 
(Fig. 2.2). This resulted in enhanced visualisation of 241 lesions detected by COE and 238 lesions 
by WL. Furthermore, NBI aided the detection of 24 lesions undetected by COE and 13 lesions 
undetected by WL. 
Lesion features were significantly associated with IPCL visibility (p<0.01). Lesions with neither 
keratosis nor erosion were more likely to have complete visibility of IPCLs, whereas keratotic 
lesions were likely to have high visibility. There was a statistical significance between the NBI 
clinical provisional diagnosis and lesion feature (p=0.01), with keratotic lesions strongly associated 
with a homogeneous or keratotic diagnosis. The IPCL pattern for each operator, as well as the final 
agreed IPCL pattern, all had a significant association with lesion feature and the NBI clinical 
diagnosis (p<0.01 for all relationships). Lesions diagnosed as a homogeneous leukoplakia or 
keratosis, non-homogeneous leukoplakia or lesion suspicious of malignancy, or lesion with 
lichenoid features were more likely to have IPCL types I or II pattern. However, when clinical 
provisional diagnoses were classified into ‘no disease’ and ‘disease’, there was no statistical 
association between clinical provisional diagnosis and IPCL pattern. Furthermore, there was no 
association between IPCL pattern and the histopathological diagnosis based on the 93 lesions with 
biopsies (Table 2.4and Table 2.5). 
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Table 2.4. Recorded details of biopsied lesions (n=93).  
Patient 
Biopsied 
lesion 
Location of 
lesion 
COE clinical provisional 
diagnosis 
WL clinical provisional 
diagnosis 
NBI IPCL 
type 
pattern 
NBI clinical provisional 
diagnosis  
Biopsy diagnosis 
1 1 Hard palate Keratosis Keratosis Type 0 Keratosis Hyperkeratosis 
2 2 Buccal mucosa Keratosis Keratosis Type 0 Keratosis Hyperkeratosis 
3 3 Tongue Oral lichen planus Oral lichen planus Type 0 Oral lichen planus Hyperkeratosis 
4 4 Lip vermillion Actinic cheilitis Actinic cheilitis Type 0 Actinic cheilitis Hyperplasia with hyperkeratosis 
5 5a Gingiva Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type 0 Non-homogeneous leukoplakia Keratosis 
6 6 Buccal mucosa Chronic hyperplastic candidosis Chronic hyperplastic candidosis Type 0 Chronic hyperplastic candidosis Chronic hyperplastic candidosis 
7 7 Gingiva Oral lichen planus Oral lichen planus Type 0 Oral lichen planus Oral lichen planus 
8 8 Lip vermillion Actinic cheilitis Actinic cheilitis Type 0 Actinic cheilitis Actinic cheilitis 
9 9a, b Floor of mouth Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type 0 Non-homogeneous leukoplakia Mild dysplasia 
10 10a Floor of mouth Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type 0 Non-homogeneous leukoplakia Moderate dysplasia 
11 11 Lip vermillion Actinic cheilitis Actinic cheilitis Type 0 Actinic cheilitis 
Actinic cheilitis with moderate 
dysplasia 
12 12a Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type 0 Non-homogeneous leukoplakia Moderately severe dysplasia 
13 13 Gingiva Oral lichen planus Oral lichen planus Type 0 Oral lichen planus Severe dysplasia 
14 14 Buccal mucosa Frictional keratosis Frictional keratosis Type I Frictional keratosis Hyperkeratosis 
15 15 Alveolar ridge Frictional keratosis Frictional keratosis Type I Frictional keratosis Hyperkeratosis 
16 16 Tongue Homogeneous leukoplakia Homogeneous leukoplakia Type I Homogeneous leukoplakia Frictional keratosis 
17 17 Buccal mucosa Lichenoid reaction Lichenoid reaction Type I Lichenoid reaction Hyperkeratosis 
18 18 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Hyperplasia with hyperkeratosis 
19 19 Tongue Homogeneous leukoplakia Homogeneous leukoplakia Type I Homogeneous leukoplakia Hyperplasia with hyperkeratosis 
20 20a Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Hyperplasia with hyperkeratosis 
21 21 Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia 
Nonspecific parakeratosis and 
chronic inflammation 
10 22 Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Hyperplasia with hyperkeratosis 
22 23 Tongue Keratosis Keratosis Type I Keratosis Chronic hyperplastic candidosis 
23 24 Tongue Homogeneous leukoplakia Homogeneous leukoplakia Type I Homogeneous leukoplakia Chronic hyperplastic candidosis 
24 25 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Chronic hyperplastic candidosis 
25 26 Tongue Oral lichen planus Oral lichen planus Type I Oral lichen planus Chronic hyperplastic candidosis 
26 27a Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Chronic hyperplastic candidosis 
27 28 Tongue Lichenoid lesion Lichenoid lesion Type I Lichenoid lesion Lichenoid reaction 
28 29 Buccal mucosa Lichenoid lesion Lichenoid lesion Type I Lichenoid lesion Lichenoid reaction 
29 30 Tongue Oral lichen planus Oral lichen planus Type I Oral lichen planus Lichenoid changes 
30 31 Buccal mucosa Lichenoid lesion Lichenoid lesion Type I Lichenoid lesion Oral lichen planus 
31 32 Buccal mucosa Lichenoid lesion Lichenoid lesion Type I Lichenoid lesion Oral lichen planus 
32 33 Tongue Oral lichen planus Oral lichen planus Type I Oral lichen planus Oral lichen planus 
33 34 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Oral lichen planus 
34 35 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Oral lichen planus 
35 36 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Oral lichen planus 
36 37 Lip vermillion Actinic cheilitis Actinic cheilitis Type I Actinic cheilitis Actinic cheilitis 
37 38 Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Lichenoid dysplasia 
38 39 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Mild lichenoid dysplasia 
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Patient 
Biopsied 
lesion 
Location of 
lesion 
COE clinical provisional 
diagnosis 
WL clinical provisional 
diagnosis 
NBI IPCL 
type 
pattern 
NBI clinical provisional 
diagnosis  
Biopsy diagnosis 
39 40 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Mild lichenoid dysplasia 
40 41 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Mild lichenoid dysplasia 
41 42 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Mild lichenoid dysplasia 
42 43 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Moderate lichenoid dysplasia 
24 44 Tongue Homogeneous leukoplakia Homogeneous leukoplakia Type I Homogeneous leukoplakia Mild dysplasia 
43 45 Buccal mucosa Frictional keratosis Frictional keratosis Type I Frictional keratosis Mild dysplasia 
44 46 Floor of mouth Not visible Homogeneous leukoplakia Type I Homogeneous leukoplakia Mild dysplasia 
45 47 Soft palate Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Mild dysplasia 
29 48a Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type I Non-homogeneous leukoplakia Mild dysplasia 
46 49 Buccal mucosa Oral lichen planus Oral lichen planus Type I Oral lichen planus Moderate dysplasia 
44 50 Floor of mouth Not visible Homogeneous leukoplakia Type I Homogeneous leukoplakia Moderate dysplasia 
10 51a Floor of mouth Homogeneous leukoplakia Homogeneous leukoplakia Type I Homogeneous leukoplakia Severe dysplasia 
47 52 Hard palate Not visible Oral lichen planus Type II Oral lichen planus Nonspecific stromal scarring 
48 53 Soft palate Vascular Vascular Type II Vascular Hyperkeratosis 
49 54 Hard palate Discoid lupus erythematosus Discoid lupus erythematosus Type II Discoid lupus erythematosus Hyperkeratosis 
50 55 Gingiva Oral lichen planus Oral lichen planus Type II Oral lichen planus Hyperplasia 
5 56 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Hyperplasia with hyperkeratosis 
19 57 Floor of mouth Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Hyperplasia with hyperkeratosis 
17 58a Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Chronic ulceration 
51 59 Buccal mucosa Lichenoid reaction Lichenoid reaction Type II Lichenoid reaction Lichenoid changes 
39 60 Lip vermillion Oral lichen planus Oral lichen planus Type II Oral lichen planus Lichenoid changes 
52 61 Buccal mucosa Lichenoid lesion Lichenoid lesion Type II Lichenoid lesion Oral lichen planus 
45 62 Hard palate Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
53 63 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
54 64 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
55 65 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
56 66 Tongue Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
57 67 Tongue Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
58 68 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Oral lichen planus 
59 69 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Lichenoid dysplasia 
60 70 Buccal mucosa Lichenoid lesion Lichenoid reaction Type II Lichenoid reaction Mild lichenoid dysplasia 
61 71a Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Mild lichenoid dysplasia 
62 72 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus 
Oral lichen planus with moderate 
dysplasia 
63 73 Lip vermillion Not visible Not visible Type II Not otherwise specifiedc Mild dysplasia 
58 74 Tongue Oral lichen planus Oral lichen planus Type II Oral lichen planus Mild dysplasia 
64 75 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Mild dysplasia 
65 76 Tongue Oral lichen planus Oral lichen planus Type II Oral lichen planus Mild dysplasia 
38 77 Buccal mucosa Oral lichen planus Oral lichen planus Type II Oral lichen planus Mild dysplasia 
66 78a Tongue Oral lichen planus Oral lichen planus Type II Oral lichen planus Mild dysplasia 
18 79a Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Mild dysplasia 
67 80a Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Mild dsyplasia 
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Patient 
Biopsied 
lesion 
Location of 
lesion 
COE clinical provisional 
diagnosis 
WL clinical provisional 
diagnosis 
NBI IPCL 
type 
pattern 
NBI clinical provisional 
diagnosis  
Biopsy diagnosis 
68 81 Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type II Non-homogeneous leukoplakia Mild dysplasia 
10 82a, b Buccal mucosa Keratosis Keratosis Type III Homogeneous leukoplakia Hyperkeratosis 
52 83a, b Gingiva Lichenoid lesion Lichenoid lesion Type III Lichenoid lesion Hyperkeratosis 
69 84 Floor of mouth Not visible Non homogeneous leukoplakia Type III Non homogeneous leukoplakia Hyperplasia 
70 85d Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type III Non-homogeneous leukoplakia Hyperplasia 
71 86a Buccal mucosa Lichenoid lesion Lichenoid lesion Type III Lichenoid lesion Lichenoid changes 
72 87a Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type III Non-homogeneous leukoplakia Lichenoid reaction 
24 88 Buccal mucosa Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type III Non-homogeneous leukoplakia Chronic hyperplastic candidosis 
38 89 Buccal mucosa Oral lichen planus Oral lichen planus Type III Oral lichen planus Mild epithelial dysplasia 
73 90a Floor of mouth Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type III Non-homogeneous leukoplakia Mild dysplasia 
73 91a, b Tongue Keratosis Keratosis Type III Non-homogeneous leukoplakia Mild dysplasia 
12 92a Floor of mouth Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type III Non-homogeneous leukoplakia Mild dysplasia 
74 93d Tongue Non-homogeneous leukoplakia Non-homogeneous leukoplakia Type IV Non-homogeneous leukoplakia Squamous cell carcinoma 
a Specifically noted as suspicious for dysplasia  
b Lesion had diagnosis changed after viewing with NBI  
c Could not diagnose based on NBI findings alone  
d Specifically noted as suspicious for malignancy  
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Table 2.5: Distribution of histopathology according to NBI IPCL pattern (n=93). 
 Histopathology 
Total 
n (%) 
Benign pathology 
n (%) 
OPMD excluding 
dysplasia 
n (%) 
Dysplasia or 
worse 
n (%) 
NBI 
IPCL 
pattern 
Type 0 5 (5.38) 3 (3.23) 5 (5.38) 13 (13.98) 
Type I 9 (9.68) 15 (16.13) 14 (15.05) 38 (40.86) 
Type II 7 (7.53) 10 (10.75) 13 (13.98) 30 (32.26) 
Type III 4 (4.30) 3 (3.23) 4 (4.30) 11 (11.83) 
Type IV 0 (0) 0 (0) 1 (1.08) 1 (1.08) 
Total 25 (26.88) 31 (33.33) 37 (39.78) 93 (100) 
 
There was 57.54% inter-observer agreement on IPCL type. ANV had a tendency to over-classify 
types 0 and I lesions as type II, whereas CSF had a tendency to over-classify type II lesions as  
type III. This resulted in ANV having only 74.1% agreement with the final, determined IPCL 
pattern compared to CSF’s 98.01%.  
There were significant associations between COE, WL and NBI clinical provisional diagnoses 
(p<0.01 for all relationships), and this is reflected in the fact that there were few changes in 
diagnoses. The clinical provisional diagnosis was changed for five lesions after using NBI  
(Table 2.4); however, only one was correctly changed from keratosis to leukoplakia suspicious for 
dysplasia. For this case, the histopathological result was mild dysplasia. 
The clinical sensitivity, specificity, PPV, NPV and accuracy for the detection of OPMDs by WL 
and NBI are summarised in Table 2.6. In contrast, the sensitivity, specificity, PPV, NPV and 
accuracy of NBI were much poorer when histopathology was the gold standard comparison  
(Table 2.7). NBI had lower values for sensitivity, specificity, PPV, NPV and accuracy than COE, 
which had 50.00%, 80.36%, 57.69%, 75.00% and 69.77% respectively. 
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Table 2.6: Efficacy of COE, WL and NBI for aiding the detection of OPMDs or worse (n=272). 
Light 
source 
Gold 
standard 
Sensitivity 
(% (95% CI)) 
Specificity 
(% (95% CI)) 
PPV 
(% (95% CI)) 
NPV 
(% (95% CI)) 
Accuracy 
(%) 
COE 
WL 
95.37 
(91.65-97.75) 
100.00 
(91.70-100) 
100.00 
(98.21-100) 
81.13 
(68.02-90.55) 96.14 
NBI 
92.38 
(88.07-95.49) 
100.00 
(92.68-100) 
100.00 
(98.21-100) 
72.24 
(61.99-84.22) 90.23 
WL 
COE 
100.00 
(98.21-100) 
81.13 
(60.02-90.55) 
95.37 
(91.65-97.75) 
100.00 
(91.70-100) 96.14 
NBI 
96.86 
(93.64-98.72) 
100 
(92.68-100) 
100 
(98.29-100) 
87.50 
(75.92-94.80) 97.43 
NBI 
COE 
100.00 
(98.21-100) 
74.63 
(62.51-84.47) 
92.38 
(88.07-95.49) 
100.00 
(92.82-100) 93.77 
WL 
100.00 
(98.29-100) 
87.50 
(72.92-94.80) 
96.86 
(92.64-98.72) 
100.00 
(92.68-100) 97.43 
COE = conventional oral examination; WL = white light modality; NBI = narrow band imaging modality;  
PPV = positive predictive value; NPV = negative predictive value; CI = confidence intervals 
 
Table 2.7: Efficacy of WL and NBI modalities on the NBI system for aiding the detection of 
dysplasia or worse in subset of lesions with biopsies (n=93). 
Light 
source 
Sensitivity 
(% (95% CI)) 
Specificity 
(% (95% CI)) 
PPV 
(% (95% CI)) 
NPV 
(% (95% CI)) 
Accuracy 
(%) 
WL 
40.54 
(24.77-57.90) 
78.57 
(65.56-88.40) 
55.56 
(35.34-74.50) 
66.67 
(53.99-77.79) 63.44 
NBI 
43.24 
(34.84-92.97) 
75.00 
(16.35-61.62) 
53.33 
(16.35-61.62) 
66.67 
(53.66-78.04) 62.37 
COE = conventional oral examination; WL = white light modality; NBI = narrow band imaging modality;  
PPV = positive predictive value; NPV = negative predictive value; CI = confidence intervals 
 
 
2.5 Discussion 
The existing literature regarding the use of NBI in the oral cavity primarily consists of retrospective 
studies investigating NBI’s ability to enhance the detection of oral cancer and/or oral epithelial 
dysplasia [44]. To the best of the authors’ knowledge, this is the first prospective clinical study that 
has specifically investigated the use of NBI on a range of OPMDs, not just dysplasia. Patient 
outcomes may be improved by detecting and monitoring OPMDs as intervention can occur before 
the disease progresses to OSCC. Although the prevalence of malignancy may be less than 1% in 
some countries, the proportion of patients presenting with an oral mucosal lesion is usually greater 
[55]. However, OPMDs tend to have more subtle changes in the epithelium than OSCCs, and can 
therefore be difficult to detect with standard WL examination [12,14]. 
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NBI is a new technology that has demonstrated its ability to aid the detection of lesions missed by 
conventional WL in other anatomical sites [22,56-58]. Use of NBI in the oral cavity is a more 
recent development, with the first published clinical use of a commercially available NBI system in 
the oral cavity by Katada et al. [36]. In this paper, NBI endoscopy aided the coincidental detection 
of two moderately differentiated OSCCs during gastrointestinal examination. Furthermore, this 
study, as well as subsequent papers, reported improved treatment outcomes when NBI was used for 
determining resection margins of OPMDs and OSCCs as resection was complete [21,35,36]. 
The effectiveness of NBI is affected by the degree in which light can penetrate the epithelium. In 
this study, the IPCL pattern was not visible for 45 out of the 217 lesions with only keratosis. 
Lesions without keratosis or erosion were significantly more likely to have completely visible 
IPCLs, and the presence of keratosis reduced IPCL visibility. This is consistent with other studies 
that have reported impaired visualisation in areas affected by hyperkeratosis associated with 
leukoplakia [21,29,38]. Despite this, most keratotic lesions were visible in this study. In another 
paper by Yang et al., the IPCL pattern was visible in areas with thin homogeneous leukoplakia, but 
became blurry, vague or completely obstructed in areas with thick homogeneous leukoplakia. With 
the latter situation, the authors suggested examining the area surrounding the lesion to determine the 
possible IPCL pattern, although they noted that this did not necessarily represent the actual pattern 
of the lesion itself [37]. Therefore, rather than assess the area surrounding the lesion, this study 
included an additional category, type 0, for lesions where the IPCL pattern was completely 
obscured within the confines of the lesion borders.  
Although several studies have used IPCL patterns to differentiate dysplasia and neoplasia from 
normal mucosa with success, this study found no statistical significance between IPCL pattern and 
the diagnosis of an OPMD or worse. These findings suggest that the vasculature of OPMDs does 
not appear distinctly pathological as it does for OSCCs. With the variety of conditions included 
under the category of OPMD as defined by WHO, the microvasculature and surface mucosal 
changes for the different types of lesions may not be as markedly different from normal tissue as 
OSCCs. However, this study is limited by the low number of dysplastic lesions and hence further 
research is warranted. 
NBI enhanced the visualisation of lesions detected by COE and WL, aided the detection of lesions 
that were undetected by COE and WL, and correctly changed the clinical provisional diagnosis of 
one lesion. In contrast, WL enhanced the overall visibility of lesions compared to COE and aided 
the detection of lesions that were missed by COE, but did not change the clinical provisional 
diagnosis of any lesion. These findings are consistent with other studies that have reported 
improved visualisation, detection rates and management of oral lesions with NBI [24,28,29]. 
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However, the advantage that WL and NBI have over COE is the fact that both have 1.5x digital 
magnification in addition to a physical zoom property that allows the endoscope tip to be as close as 
2 mm away from the mucosal surface [19]. Consequently, it is possible to visualise lesions and the 
detailed features of lesions that may otherwise be missed from an extra-oral point of view. 
In this study, the provisional diagnoses of three lesions were incorrectly changed to an OPMD as 
the examiner interpreted their IPCL pattern as type III. Of these, the reviewer classed two as having 
type II, but only one was ultimately agreed to as having IPCL type II. This highlights the subjective 
difficulty in interpretation of the nature of IPCLs, and unsurprisingly resulted in a low inter-
observer agreement of 57.54%. However, the low inter-observer agreement was largely due to the 
difference in training and experience between the two clinicians. It is well known that there is a 
degree of training required to properly interpret IPCL patterns, and a steep learning curve associated 
with using NBI and interpreting mucosal changes and underlying microvasculature [24]. Another 
factor to be considered is the discrepancy in image quality between live recordings and video 
recordings, with the former having superior resolution and clarity. 
The high sensitivity, PPV, NPV and accuracy of NBI compared to COE or WL confirms that NBI 
has low rates of false negatives. NBI had lower specificity than both COE and WL, suggesting that 
there is a higher rate of false negatives with NBI. However, the gold standard comparison was 
either COE or WL, both of which detected fewer lesions than NBI. Although this study had a 
clinical focus in order to compare NBI with existing gold standards – namely, COE for non-
endoscopic visual assessment and WL with magnification when using the endoscope, the concern 
with using another light as the gold standard comparison is that new lesions were technically 
considered false positives if it was not detected with the other light modality. Furthermore, this 
study aimed to use NBI for clinical assessment OPMDs, and thus the value of histopathology as a 
gold standard is diminished. This is one limitation of the study that may affect the accuracy of the 
estimation of specificity, particularly for presence of underlying oral epithelial dysplasia. However, 
short of causing more harm to patients by unethically biopsying all lesions in all patients regardless 
of clinical suspicion; this was the most appropriate alternative.  
For the subset of lesions that were biopsied however, the sensitivity, specificity, PPV, NPV and 
accuracy was lower for NBI when histopathology was used as the gold standard. This is attributable 
to the smaller sample size, the majority of biopsies taken without input from NBI, lack of multi-site 
biopsies, and examination of specimens by one of a few pathologists involved in the study. 
Nonetheless, the poorer efficacy values are consistent with the fact that there appears to be no clear 
association between IPCL pattern type and histopathology in our study. Given how many existing 
oral visualisation adjuncts tend to be poor at differentiating benign and inflammatory lesions from 
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OPMDs and neoplastic lesions [45,46,59-61], further research is required to determine if there are 
any differences in the microvascular appearance of these lesions by NBI. Future research should 
also consider using NBI to select multiple biopsy sites of a lesion based on their vasculature, as 
previous research have reported significantly lower under-diagnosis rates with multi-site biopsies 
than with single-site biopsies [52]. 
Use of NBI in the oral cavity does present with some challenges. Learning how to position the 
endoscope to provide a clear image on the monitor resulted in poor ergonomics at times, and this is 
further exacerbated if the monitor was poorly positioned in relation to the operator. Despite the fact 
that the NBI system is mounted on a freely moveable frame, the device is large and not overly 
portable. A clinical assistant is recommended for aiding the retraction of oral tissues to improve the 
clinician’s ability to accurately place the endoscope in an ergonomic position, particularly when 
observing intra-oral areas with overlapping or mobile tissues.  
This study was conducted in a specialist oral medicine and pathology clinic, with a sole oral 
medicine specialist undertaking the examinations. Results from this study cannot be generalised to 
the community setting or to general practitioners. With the amount of training required to correctly 
use and interpret NBI findings, and the high cost of the system, use of NBI is not recommended for 
general medical or dental practitioners and instead should be limited to specialist or tertiary referral 
centres. Examination bias may be present in this study as only one operator examined the non-
randomised cohort of patients with all three lights consecutively. Furthermore, the examiner had 
previously examined the majority of lesions, and this was possibly a confounding factor that biased 
provisional diagnoses despite the fact that the examiner was blinded to pre-existing notes and 
histopathological reports. Increasing the number of new lesions and having multiple examiners 
blinded to the results of the other lights would have provided a more accurate representation of the 
efficacy of a particular light; however, the NBI system is designed with both WL and NBI 
modalities, and as such the NBI modality is not to be used in isolation. Indeed, its WL feature 
should be used before the NBI feature to minimise false interpretation. Until further research clearly 
demonstrates the superiority of NBI over WL alone for aiding the detection of OPMDs or worse, 
NBI should be reserved as a visualisation adjunct to WL examination and not as a direct 
replacement. 
 
2.6 Conclusions 
Although the microvascular IPCL pattern of OPMDs may not distinctly correlate with pathological 
diagnoses of OPMDs, NBI demonstrates great utility as a visualisation adjunct for detecting and 
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visualising OPMDs as it has high diagnostic accuracy and can aid the detection of lesions that may 
not be identified by COE or WL examination alone. Enhanced detection and monitoring of OPMDs 
with NBI technology has the potential to improve patient outcomes; an area of research that 
requires longitudinal studies. 
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3.1 Abstract 
Objectives: To correlate mRNA and microRNA (miRNA) expression profiles at the primary tumour 
margins of oral cavity squamous cell carcinoma defined by Narrow Band Imaging (NBI) and white 
light (WL).  
Methods: A sample was taken from the NBI margin, WL margin and the centre of the tumour of 
eighteen resected primary oral squamous cell carcinomas. RNA was isolated from each sample and 
hybridised to mRNA and miRNA gene expression microarrays (GeneChip® Human Genome U133 
Plus 2.0 and Agilent Human v16 miRNA 8x60K microarrays respectively). Following data 
normalisation, differentially-expressed (DE) genes and pairwise differentially expressed genes were 
identified. Gene Ontology term enrichment and pathway annotation was undertaken to determine 
the presence of any clustering DE genes. miRNA was integrated with mRNA, and significant 
miRNA and mRNA pairs were mapped using GeneGo. 
Results: A total of 4 794 genes and 137 miRNAs were found to be DE. Tumour samples were 
clustered separately from WL and NBI samples; however, the separation between NBI and WL was 
less distinct. When integrating DE miRNA with DE mRNA, there were 91 potential miRNA-
mRNA pairs (28 miRNA with 87 genes) identified. Seventeen miRNAs in the integration dataset 
were up-regulated in the tumour core when compared to tissue at the NBI and/or WL margin, and 
eleven were down-regulated. The highest up-regulated miRNA in the tumour was miR-21, whereas 
the most down-regulated was miR-30a. 
Conclusion: The type of miRNAs and their associated genes expressed at the tumour was altered 
compared to the NBI margin. Therefore, the NBI margin was more likely to contain molecularly 
normal cells. The use of NBI to determine resection margins may improve the success rate of 
OSCC treatment.  
 
 
 
Keywords: narrow band imaging; oral cancer; mRNA; microRNA; tumour margins; molecular 
pathways  
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3.2 Introduction 
Oral cancer is the eighth and thirteenth most common cancers in the world for males and females 
respectively [2]. The five year survival rate has remained at around 50% as more than half of 
patients present with stage III or IV oral cancer [2,43,62]. Despite advances in treatment for this 
disease in the past three decades, treatment for late-stage cancers is associated with considerable 
morbidity and mortality as they are typically painful, invasive and disfiguring [12,13]. Prognosis is 
further reduced when oral cancers are not resected with histologically proven clear surgical margins 
[63]. However, the use of histology alone as a prognostic tool is not entirely dependable as there is 
still a high rate of treatment failure [64]. This may be due to the presence of tumour-related genes in 
margins deemed clear by histopathology [65]. 
Over-expression of oncogenes and under-expression of tumour suppressor genes results in tumour 
development. Messenger RNA (mRNA) and microRNA (miRNA) are both implicated in 
tumorigenesis as both are involved in the expression of genes involved in cell differentiation, 
proliferation and apoptosis [66]. There is an interplay between mRNA and miRNA as specific 
miRNAs bind to their target mRNA(s) to regulate gene expression [67]. Both have a diagnostic and 
prognostic value as increased or decreased expression of particular mRNAs and miRNAs associated 
with oncogenesis may be used to determine the presence of cancerous cells and tissues [66,67]. 
Recent advances in visualisation aids for oral cancer have given clinicians new technologies that 
may be used for delineating resection margins. One such imaging modality that has been shown to 
be superior to white light for determining surgical margins in superficial head and neck cancers is 
Narrow Band Imaging (NBI; Olympus Medical Systems Corporation, Tokyo, Japan) [21,35,68]. 
NBI is an endoscopic technique that utilises filtered blue (415±15 nm) and green (540±15 nm) light 
in NBI mode to enhance the visualisation of the mucosal and submucosal vasculature and mucosal 
surface texture. As neoplastic tissues have an abnormal microvasculature pattern, normal mucosa 
can be delineated from abnormal [12,13]. 
A comparison between the molecular genetic activity at margins defined by NBI and the tumour 
may provide a clearer picture in terms of malignant progression, recurrence and risk prediction. 
This study aims to investigate this by correlating mRNA and miRNA gene expression profiles at 
primary tumour margins defined by NBI and WL. 
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3.3 Materials and Methods 
3.3.1 Study population and research setting 
Between 2010 and 2011, patients with oral squamous cell carcinoma (OSCC) planned for surgical 
resection were prospectively recruited from the multidisciplinary head and neck cancer clinic at The 
Royal Brisbane and Women’s Hospital, Herston Australia. Eighteen patients, unrestricted by age or 
sex, with primary intra-oral tumours that could be completely visualised by the NBI nasoendoscope 
were enrolled in the study after informed consent.  
Sample processing and laboratory analysis of biopsies were performed at The University of 
Queensland Centre for Clinical Research (UQCCR), Herston, Australia, and the Molecular and 
Clinical Pathology Research Laboratory (MaCH R), Woolloongabba, Australia. The Queensland 
Facility for Advanced Bioinformatics (QFAB) undertook initial bioinformatics data analysis and 
reporting. This study was covered under ethics approvals (HREC/08/QRBW20 and 
HREC/10/QRBW336). 
 
3.3.2 Surgical margins and tissue sampling 
Prior to the day of surgery, a consulting physician examined the primary tumour with white light 
(WL) followed by NBI equipped with the Olympus NBI ENF-VQ nasoendoscope, CLV-180 light 
source which has the NBI filter, and the CV-180 processor (Olympus Medical Systems, Tokyo, 
Japan). Digital video recordings and still photographs were taken. On the day of the surgical 
procedure, the surgeon defined the WL tumour margin using WL examination and palpation. 
Following visualisation of the NBI video and photographs, the NBI tumour margin was determined. 
The final surgical margins for both WL and NBI were expanded by at least 5 mm to provide a clear 
surgical margin [69,70]. 
Following resection, a 4 mm biopsy was taken firstly from the NBI surgical margin (referred to as 
‘NBI’ hereafter), then at the WL surgical margin (referred to as ‘WL’ hereafter), and finally the 
centre of primary tumour (referred to as ‘T’ hereafter). Samples were not taken at the very edge of 
the NBI and WL change but instead 5mm away from the visible tissue abnormalities in order to 
minimise sampling error across the region of change. The exact position of each biopsy on the 
resected tissue was photographed. Normal saline was used to rinse the surgical blade and forceps 
used between biopsies to avoid cross-contamination.  
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Within half an hour of being sampled, specimens were placed in RNAlater RNA stabilisation 
solution (Ambion, Life Technologies, Carlsbad, CA, USA) and frozen at -80°C until RNA 
isolation. Digital photographs of the macroscopic surgical specimen were labelled with the biopsy 
sites. Histopathology was reported on the surgical specimen by anatomical pathologists with 
expertise in head and neck oncology according to accepted guidelines [71].  
 
3.3.3 RNA isolation 
Frozen tissue was manually ground to a fine powder consistency in liquid nitrogen and incubated in 
500 µL lysis buffer (Buffer RLT, Qiagen, Hilden, Germany) with 200 ng of Proteinase K 
(Invitrogen, Life Technologies, Carlsbad, USA) for 16-20 hours with mixing at 37°C. Following 
incubation, 200 µL of lysate was used with TRIzol® Reagent (Invitrogen, Life Technologies, 
Carlsbad, USA) for RNA isolation. The remaining lysate was stored at  
-80°C. The manufacturer’s protocol was followed for phase separation and RNA isolation; 
however, to increase nucleic acid recovery, 10 µg of RNase-free glycogen was added as a carrier 
and the mixture incubated overnight at -20°C. Isolated RNA was then resuspended in 40 µL of 
nuclease-free water and stored at -80°C. The TURBO DNA-free™ Kit (Ambion, Life 
Technologies, Carlsbad, USA) and sodium acetate precipitation were used to remove DNA and 
purify RNA respectively. A NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, 
USA) and Qubit® fluorometer (Invitrogen, Life Technologies, Carlsbad, USA) quantified RNA and 
an Agilent 2100 Bionalyzer with the RNA 6000 Nano kit (Agilent Technologies, Santa Clara, CA, 
USA) assessed RNA integrity. 
 
3.3.4 Gene expression profiling 
A total of 54 samples – three (NBI, WL and T) from each of the 18 patients – were hybridised to 
gene expression microarrays. For RNA microarray hybridisation, 100 ng of RNA was inputted to 
the GeneChip 3’ IVT Express Kit using the standard protocol (Affymetrix, Santa Clara, CA, USA). 
The amplified RNA (aRNA) was then hybridised to the GeneChip® Human Genome U133 Plus 2.0 
Array (Affymetrix, Santa Clara, CA, USA). An Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA) was used prior to array hybridisation for quality control (QC) of amplified 
RNA (aRNA) size distribution and yield pre- and post-aRNA fragmentation.  
For miRNA microarray hybridisation, the standard protocol for Agilent Human v16 miRNA 8x60K 
microarrays (Agilent Technologies, Santa Clara, CA, USA) was performed. 100 ng of input RNA 
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with the optional spike-in controls were used following the specified procedure. The Small RNA 
Kit (Agilent Technologies, Santa Clara, CA, USA) was used on the Agilent 2100 Bioanalyzer 
(Agilent, Böblingen, Germany) prior to array hybridisation for QC. 
 
3.3.5 Bioinformatics 
3.3.5.1 Quality control and normalisation of array data 
Two discrete QC pipelines, affyAnalysisQC [72]and simpleaffy [73], were used to process mRNA 
data, and the Agilent Feature Extraction software was used to process miRNA data from the 54 
arrays. Outliers were removed from the datasets after assessing for good RNA quality and 
consistent hybridisation quality. Robust multi-array average (RMA) was used to normalise data 
from arrays. Specifically, the GeneChip robust multi-array analysis (GCRMA) normalisation 
method was chosen to normalise data from good quality mRNA arrays as it took into account 
sequence-specific affinities of the GeneChip probes and gave the greatest consistency in the 
normalised expression data across all arrays [74]. 
3.3.5.2 Identification of differentially-expressed genes 
Probes with coefficient of variation (CV) <0.1 across all arrays were excluded from the datasets 
after normalisation. Using the maanova software package, the normalised, filtered data was tested 
for genes significantly differentially-expressed (DE) in the NBI-T, WL-T and NBI-WL pairwise 
comparisons [75]. A linear model was applied to the (log-transformed) expression data of the 
remaining probes and a paired one-way ANOVA was computed. The Benjamini and Hochberg 
(BH) procedure was used to adjust results for multiple testing. Probes that were not DE were 
filtered from the dataset [76]. 
3.3.5.3 Identification of pairwise differentially-expressed genes 
The limma software package was used to test the remaining probes in the datasets for pairwise 
significantly DE genes [77]. A linear model was applied to the (log-transformed) expression data 
and paired t-test with BH adjustment was calculated for the NBI-T, WL-T and NBI-WL pairwise 
comparisons. The nominal baseline for DE gene interpretation of the magnitude and direction of 
regulation in the WL and NBI margins was the tumour core expression level. 
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3.3.5.4 Gene ontology and pathway annotation  
The hypergeometric test in the GOstats software package was used to analyse Gene Ontology (GO) 
term enrichment for the molecular function (MF), biological process (BP), and cellular component 
(CC) domains [78]. The p-value was adjusted with the false discovery rate (FDR) method, and GO 
terms with a p-value of <0.05 were considered significantly enriched. All genes (Entrez IDs) on 
probes that passed the CV filtering step were used as the background for the GO term enrichment 
analysis. The MetaCore™ pathway analysis tool by GeneGo (www.thomsonreuters.com; 
www.genego.com) was used for pathway annotation of the significantly DE genes from the three 
pairwise comparisons. 
3.3.5.5 Clustering of differentially-expressed genes 
Principal component analysis (PCA) using the mixOmics software package was conducted on the 
normalised expression data for probes remaining after CV filtering but before ANOVA/DE 
filtering, to determine whether there was any clustering of DE genes [79].  
3.3.5.6 Identification of miRNA targets 
To determine miRNA targets, we searched for molecular genes involved in various cellular 
processes involved in carcinogenesis using multiple prediction programs, and cross-referenced 
these to obtain the most accurate data available. Databases included (http://www.mirbase.org/, 
http://www.microrna.org/, http://www.pictar.org/, and http://dorina.mdc-berlin.de/). Prediction 
scores were computed using the miRanda database of highly conserved targets with good mirSVR 
scores.  
3.3.5.7 Integration of miRNA and mRNA 
Data was simplified by group analysis to produce a generalised model. This involved assuming 
expression profiles for each patient were similar across the T, WL and NBI regions, which therefore 
allowed the median mRNA and miRNA expression to represent the data samples. Sparse partial 
least squares (sPLS) was applied to identify correlated profiles between mRNA and miRNA. For 
each pair selected by sPLS, Pearson’s correlation with BH adjustment was used to test for 
significance. Stability analysis was performed on selected mRNAs, and results were matched with 
those from the group analysis. Pairs with FDR < 0.05 were identified as significant. 
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3.3.5.8 Mapping miRNA and mRNA relationships 
Significant miRNA and mRNA relationships were mapped using the ‘Build Network’ tool on 
GeneGo (www.genego.com). The shortest pathways between miRNA and mRNA were considered 
for simplicity. 
 
 
3.4 Results 
Three tissue samples from a total of 18 patients were taken, one from the tumour core, the WL 
margin, and the NBI margin. This gave a total of 54 mRNA arrays and of these, 49 array data 
underwent the bioinformatics workflow as 5 arrays of the NBI margin were identified as outliers 
and consequently excluded from further analysis. A total of 38 989 probes were retained in the 
mRNA dataset after probes with low variance were removed by data normalisation and CV 
filtering. For miRNA, there were 54 arrays; however, only 47 arrays underwent the bioinformatics 
workflow as 13 arrays of the NBI margin were considered outliers and thus excluded from analysis. 
There was good RNA quality and consistent hybridisation quality in most arrays. 
In the mRNA dataset, there was a total of 7 633 probes representing 4 794 genes (Gene Symbols) 
that were significantly DE (adjusted p-value <0.01). In contrast, a total of 137 miRNA probes were 
found to be DE in at least one of the three tissue groups. There was a higher number of significantly 
DE miRNAs between the NBI and T sites (109 DE miRNAs) than between the WL and T sites (81 
DE miRNAs), and only a few between the WL and NBI sites (7 DE miRNAs). The distribution of 
miRNAs is summarised in Figure 3.1. 
 
Figure 3.1. Venn diagram of the DE miRNAs from the NBI-T, WL-T and NBI-WL comparison 
groups.  
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Molecular divergence was more apparent between the NBI and tumour sites (4 387 DE genes) than 
between the WL and tumour sites (3 266 DE genes). There were no obvious molecular divergence 
between the NBI and WL. This is supported by clustering by PCA for both mRNA and miRNA. 
The PCA plots revealed the presence of a first discriminatory component that separated of tumour 
samples from WL and NBI samples; however, the separation between NBI and WL was less 
distinct (Figure 3.2and Figure 3.3).  
 
 
Figure 3.2. Principal Component Analysis (PCA) plot representing Dimension 1 vs Dimension 2 for 
mRNA. 
Each coloured number represents the location of a sample from a particular patient. Blue represents narrow band 
imaging (NBI) samples, red represents tumour (T) samples, and those in green represents white light (WL) samples. 
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Figure 3.3. Principal Component Analysis (PCA) plot representing Dimension 1 vs Dimension 2 for 
miRNA. 
Each coloured number represents the location of a sample from a particular patient. Blue represents narrow band 
imaging (NBI) samples, red represents tumour (T) samples, and those in green represents white light (WL) samples. 
 
Gene ontology analysis based on the 4 794 DE genes revealed that 58% and 64% of GO 
associations for the NBI and WL margins respectively were involved in the BP domain, which 
included processes such as cell cycle, development, regulation, and signalling. There were 38% GO 
associations for NBI and 26% for WL that pertained to the CC category, which is mostly associated 
with intracellular components. Only 12% and 10% of GO associations for NBI and WL respectively 
were related to the MF domain, which involves non-covalent binding and activities associated with 
enzymes, receptors and transporters. For miRNA however, the top ten GO processes related to the 
MF domain, specifically, cellular response to chemical stimuli (Figure 3.4). 
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Figure 3.4. Top 10 Gene Ontology Processes enriched in at least 1 of the 3 significant differentially 
expressed miRNAs comparison groups. 
The orange bar corresponds to the differentially expressed miRNAs from the NBI-T comparison, the blue bar for the 
WL-T comparison, and red bar for the NBI-WL comparison. 
 
The top pathways enriched in the DE genes from the NBI-T mRNA comparison mainly related to 
cell adhesion and development, muscle function and the immune response. In contrast, the top ten 
pathways enriched in the DE from the WL-T mRNA comparison were associated with cell 
adhesion, development, and carcinoma progression. For miRNA, the only pathway significantly 
represented for both the NBI-T and WL-T comparisons was a development pathway associated with 
miRNA-dependent inhibition of epithelial-mesenchymal transition (EMT). 
As there were different numbers of DE samples between the miRNA and mRNA datasets, the 
integration analysis only used the 41 common samples (Table 3.1).  
 
Table 3.1: Breakdown of the dataset used for integration of miRNA and mRNA. 
 
Patient 
Total 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
NBI 1 1 1 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 7 
T 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 17 
WL 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 17 
Total 3 3 3 3 2 2 2 3 2 3 2 2 1 2 2 2 2 2 41 
‘1’ indicates that both a miRNA and mRNA sample is present 
NBI = narrow band imaging margin; T = tumour core; WL = white light margin 
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A total of 91 potential miRNA-mRNA pairs (28 miRNA with 87 genes) were identified when 
integrating DE miRNA with DE mRNA. Table 3.2 summarises the results of significant miRNA-
mRNA pairs based on the false discovery rate (FDR), and each miRNA should be treated 
independently of the others. All pairs have been experimentally validated according to miRTarBase. 
Twenty eight networks, one for each miRNA, were created in GeneGo (Appendices II and III). Two 
pairs of networks, namely miR-23b and miR-26a, and miR-31 and miR-218, had overlapping 
sections of pathways and were therefore merged together (Appendix IV). All miRNAs were located 
in the cytoplasm and had a tendency to interact with other components in the cytoplasm or at the 
nucleus, rather than with components within or outside the extracellular membrane (Appendix III). 
Only nine miRNA-mRNA pairs had a known direct relationship, and these were let-7c to HMGA2, 
miR-17 to DNAJC27, miR-21 to NFIB, miR-26a to CPEB3, miR-218 to SOST, miR-218 to DKK2, 
miR-218 to SFRP2, and miR-224 to EYA4. For the majority of miRNA and mRNA relationships, 
the interaction was often via intermediary genes. A few genes could not be included in their 
respective networks, and these included AGPAT5, ARSG, C12orf65 and ENPP5. Seventeen 
miRNAs in the integration dataset were up-regulated in the tumour core when compared to tissue at 
the NBI and/or WL margin, and eleven were down-regulated. Of these, the highest up-regulated 
miRNA in the tumour was miR-21, which had an 8.75-fold increase, whereas the most down-
regulated miRNA was miR-30a, which decreased 4.15-fold (Table 3.3). 
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Table 3.2: Summary of the significant miRNA-mRNA pairs. 
miRNA mRNA probeId Gene Full name of gene Correlation FDR Stability 
hsa-let-7c 239660_at 
1561633_at 
231953_at 
202705_at 
204826_at 
214793_at 
204827_s_at 
223984_s_at 
RALGAPA2
a 
HMGA2
b 
BPTF
a 
CCNB2
a
 
CCNF
a
 
DUSP7
a
 
CCNF
a
 
NUPL1
a
 
Ral GTPase activating protein, alpha subunit 2 (catalytic) 
high mobility group AT-hook 2 
bromodomain phd finger transcription factor 
cyclin B2 
cyclin F 
dual specificity phosphatase 7 
cyclin F 
nucleoporin like 1 
-1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.34e-02 
1.34e-02 
1.71e-02 
1.71e-02 
1.71e-02 
1.71e-02 
1.52e-02 
1.68e-02 
0.44 
0.39 
0.39 
0.28 
0.28 
0.28 
0.22 
0.22 
hsa-miR-7 221019_s_a t  
222483_at 
COLEC12
a
 
EFHD2
a
 
collectin sub-family member 12 
EF-hand domain family, member D2 
1.00 
-1.00 
3.66e-03 
2.67e-03 
0.11 
0.11 
hsa-miR-17 205824_at 
1554309_at 
223504_at 
227803_at 
202073_at 
203204_s_a t  
HSPB2
a
 
EIF4G3
a
 
DNAJC27
b 
ENPP5
c 
OPTN
a
  
KDM4A
a
 
heat shock 27kDa protein 2 
eukaryotic translation initiation factor 4 gamma, 3 
DnaJ (Hsp40) homolog, subfamily C, member 27 
ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative) 
optineurin 
lysine (K)-specific demethylase 4A 
1.00 
-1.00 
1.00 
1.00 
1.00 
-1.00 
2.16e-02 
2.13e-02 
2.13e-02 
3.70e-02 
2.16e-02 
3.70e-02 
0.94 
0.83 
0.67 
0.67 
0.50 
0.50 
hsa-miR-18b 201150_s_a t  
224753_at 
34187_at 
TIMP3
a
 
CDCA5
a
 
RBMS2
a
 
tissue inhibitor of metalloproteinases-3 
cell division cycle associated 5 
RNA binding motif, single stranded interacting protein 2 
1.00 
-1.00 
-1.00 
4.44e-02 
4.44e-02 
4.44e-02 
1.00 
1.00 
1.00 
hsa-miR-21 211467_s_a t  NFIB
b 
nuclear factor 1 B-type 1.00 3.31e-02 0.39 
hsa-miR-23b 1555250_a_ a t  
208832_at 
CPEB3
a
 
ATXN10
a 
cytoplasmic polyadenylation element binding protein 3 
ataxin 10 
-1.00 
-1.00 
8.96e-03 
8.96e-03 
0.33 
0.17 
hsa-miR-24 213226_at 
225516_at 
CCNA2
a
 
SLC7A2
a
 
cyclin A2 
solute carrier family 7 (cationic amino acid transporter, y+ system) 
1.00 
-1.00 
9.16e-04 
5.15e-04 
* 
* 
hsa-miR-25 205226_at PDGFRL
a 
platelet-derived growth factor receptor-like -1.00 4.21e-02 0.78 
hsa-miR-26a 1555250_a_ a t  
206074_s_a t  
225478_at 
229078_s_a t  
207563_s_a t  
239054_at 
CPEB3
b 
HMGA1
a 
MFHAS1
a
 
KIAA1704
a
 
OGT
a
 
SFMBT1
a
 
cytoplasmic polyadenylation element binding protein 3 
high mobility group AT-hook 1 
malignant fibrous histiocytoma amplified sequence 1 
aka. LSR7 (lipopolysaccharide-specific response protein 7) 
O-linked N-acetylglucosamine transferase 
Scm-like with four mbt domains 1 
-1.00 
1.00 
1.00 
-1.00 
1.00 
-1.00 
2.09e-02 
1.89e-02 
1.89e-02 
1.89e-02 
1.89e-02 
2.09e-02 
0.72 
0.67 
0.61 
0.61 
0.56 
0.22 
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miRNA mRNA probeId Gene Full name of gene Correlation FDR Stability 
hsa-miR-26b 1559419_at 
205594_at 
230529_at 
220586_at 
222393_s_a t  
206686_at 
CACNB2
a
 
ZNF652
a
 
HECA
a
 
CHD9
a
 
NAA50
a
 
PDK1
a
 
calcium channel, voltage-dependent, beta 2 subunit 
zinc finger protein 652 
headcase homolog 
chromodomain helicase DNA binding protein 9 
N(alpha)-acetyltransferase 50, NatE catalytic subunit 
pyruvate dehydrogenase kinase, isozyme 1 
-1.00 
-1.00 
-1.00 
-1.00 
1.00 
1.00 
4.82e-02 
2.46e-02 
2.46e-02 
2.46e-02 
4.82e-02 
4.82e-02 
0.33 
0.33 
0.33 
0.28 
0.22 
0.17 
hsa-miR-30a 212220_at 
212327_at 
PSME4
a 
LIMCH1
a
 
proteasome (prosome, macropain) activator subunit 4 
LIM and calponin homology domains 1 
1.00 
-1.00 
7.12e-04 
6.01e-05 
0.17 
0.11 
hsa-miR-30c 220511_s_a t  
227697_at 
DLC1
a
 
SOCS3
a
 
deleted in liver cancer 1 
suppressor of cytokine signaling 3 
-1.00 
1.00 
5.67e-03 
1.12e-02 
0.72 
0.72 
hsa-miR-31 218340_s_a t  
222037_at 
UBA6
a
 
MCM4
a
 
ubiquitin-like modifier activating enzyme 6 
minichromosome maintenance complex component 4 
1.00 
1.00 
2.06e-03 
1.11e-03 
0.33 
0.33 
hsa-miR-93 201082_s_a t  DCTN1
a
 dynactin 1 -1.00 3.33e-02 0.67 
hsa-miR-100 203296_s_at ATP1A2
a 
ATPase, Na+/K+ transporting, alpha 2 polypeptide -1.00 1.24e-03 0.78 
hsa-miR-101 215073_s_at 
229092_at 
237159_x_at 
NR2F2
a
 
NR2F2
a
 
AP1S3
a
 
nuclear receptor subfamily 2, group F, member 2 
nuclear receptor subfamily 2, group F, member 2 
adaptor-related protein complex 1, sigma 3 subunit 
-1.00 
-1.00 
1.00 
2.28e-02 
3.82e-02 
3.82e-02 
0.78 
0.78 
0.72 
hsa-miR-103a 214119_s_at FKBP1A
a
 FK506 binding protein 1A, 12kDa -1.00 2.59e-02 0.44 
hsa-miR-125b 228195_at 
235783_at 
238530_at 
208830_s_at 
C2orf88
a 
MRTO4
a
 
NNT
a
 
SUPT6H
a
 
chromosome 2 open reading frame 88 
mRNA turnover 4 homolog 
nicotinamide nucleotide transhydrogenase 
suppressor of Ty 6 homolog 
-1.00 
1.00 
-1.00 
1.00 
3.64e-02 
2.96e-02 
4.00e-03 
2.08e-02 
0.39 
0.33 
0.33 
0.28 
hsa-miR-130b 205868_s_a t  
223476_s_a t  
PTPN11
a 
C12orf65
c 
tyrosine-protein phosphatase non-receptor type 11 
chromosome 12 open reading frame 65 
-1.00 
-1.00 
1.95e-02 
1.17e-02 
0.50 
0.50 
hsa-miR-132 222385_x_at  
214319_at 
212326_at 
217167_x_at  
235086_at 
1569599_at 
206553_at 
SEC61A1
a 
FRY
a
  
VPS13D
a
 
GK
a
 
THBS1
a
 
SAMSN1
a
 
OAS2
a 
sec61 alpha 1 subunit 
furry homolog 
vacuolar protein sorting 13 homolog D 
glycerol kinase 
thrombospondin 1 
SAM domain, SH3 domain and nuclear localization signals 1 
2'-5'-oligoadenylate synthetase 2, 69/71kDa 
-1.00 
1.00 
1.00 
-1.00 
-1.00 
-1.00 
-1.00 
3.17e-02 
6.31e-03 
4.46e-02 
3.17e-02 
3.17e-02 
4.46e-02 
3.17e-02 
0.39 
0.33 
0.28 
0.28 
0.28 
0.22 
0.22 
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miRNA mRNA probeId Gene Full name of gene Correlation FDR Stability 
hsa-miR-181a   221185_s_a t  
204531_s_a t  
225683_x_at  
205648_at 
226589_at 
1558254_s_ a t  
IQCG
a 
BRCA1
a
 
PHPT1
a
 
WNT2
a
 
TMEM192
a
 
SRPK2
a
 
IQ motif containing G 
Breast cancer 1 
phosphohistidine phosphatase 1 
wingless-type MMTV integration site family member 2 
transmembrane protein 192 
SRSF protein kinase 2 
1.00 
1.00 
-1.00 
1.00 
-1.00 
1.00 
4.65e-02 
4.65e-02 
4.65e-02 
4.65e-02 
4.65e-02 
4.65e-02 
0.72 
0.67 
0.67 
0.61 
0.50 
0.44 
hsa-miR-183 209895_at 
217100_s_a t  
205868_s_a t  
230134_s_a t  
PTPN11
a 
UBXN7
a
 
PTPN11
a
 
RC3H2
a
 
tyrosine-protein phosphatase non-receptor type 11 
UBX domain protein 7 
tyrosine-protein phosphatase non-receptor type 11 
ring finger and CCCH-type domains 2 
-1.00 
-1.00 
-1.00 
-1.00 
3.82e-02 
4.43e-02 
4.21e-02 
3.82e-02 
0.50 
0.50 
0.39 
0.28 
hsa-miR-193b 218574_s_a t  
232164_s_a t  
LMCD1
a
 
EPPK1
a
 
LIM and cysteine-rich domains 1 
epiplakin 1 
1.00 
-1.00 
4.88e-03 
7.69e-03 
0.89 
0.72 
hsa-miR-196a 212805_at 
203820_s_a t  
PRUNE2
a 
IGF2BP3
a
 
prune homolog 2 (Drosophila) 
insulin-like growth factor 2 mRNA binding protein 3 
1.00 
-1.00 
4.26e-02 
4.26e-02 
0.56 
0.50 
hsa-miR-218 1552632_a_ a t  
207143_at 
222660_s_a t  
223869_at 
228988_at 
232007_at 
215145_s_a t  
203542_s_a t  
219908_at 
223121_s_a t  
ARSG
c 
CDK6
b
 
RNF38
a
 
SOST
b
 
ZNF711
a
 
AGPAT5
c
 
CNTNAP2
a
 
KLF9
a 
DKK2
b 
SFRP2
b
 
arylsulfatase G 
cyclin-dependent kinase 6 
ring finger protein 38 
sclerostin 
zinc finger protein 711 
1-acylglycerol-3-phosphate O-acyltransferase 5 
contactin associated protein-like 2 
Kruppel-like factor 9 
Dickkopf-related protein 2 
secreted frizzled-related protein 2 
-1.00 
1.00 
1.00 
1.00 
-1.00 
-1.00 
1.00 
-1.00 
-1.00 
-1.00 
2.05e-02 
3.28e-02 
4.44e-02 
2.05e-02 
4.44e-02 
4.44e-02 
4.44e-02 
4.44e-02 
2.05e-02 
4.44e-02 
0.39 
0.39 
0.39 
0.39 
0.39 
0.39 
0.33 
0.28 
0.28 
0.28 
hsa-miR-222 201647_s_a t  
206074_s_a t  
202384_s_a t  
224525_s_a t  
SCARB2
a
 
HMGA1
a
 
TCOF1
a
 
OLA1
a
 
scavenger receptor class B, member 2 
high mobility group AT-hook 1 
Treacher Collins-Franceschetti syndrome 1 
Obg-like ATPase 1 
1.00 
1.00 
1.00 
-1.00 
1.36e-02 
2.65e-02 
1.36e-02 
1.36e-02 
0.50 
0.50 
0.44 
0.39 
hsa-miR-224 207327_at EYA4
b 
eyes absent homolog 4 1.00 2.10e-02 1.00 
hsa-miR-744 203184_at 
222625_s_a t  
FBN2
a
 
NDE1
a
 
fibrillin 2 
nudE neurodevelopment protein 1 
1.00 
1.00 
2.73e-04 
6.58e-04 
0.11 
* 
a miRNA interacts via intermediary genes 
b miRNA directly targets gene 
c No previously recorded interaction according to GeneGo 
* Corresponding mRNA was not selected during the stability analysis 
FDR = False discovery rate
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Table 3.3: Significantly differentially expressed miRNAs with fold change of more than 2. 
ProbeID GeneID t-statistic 
Adjusted  
p value 
B-
statistic 
Expression  
Fold change 
(Tumour / 
NBI or WL) 
A_25_P00010975 hsa-miR-21 -11.32 1.12E-08 14.91 Over 8.75 
A_25_P00013215 hsa-miR-31* -3.12 6.64E-03 -2.90 Over 3.23 
A_25_P00012133 hsa-miR-224 -4.47 4.57E-04 0.31 Over 3.11 
A_25_P00012097 hsa-miR-183 -5.35 9.87E-05 2.48 Over 2.09 
A_25_P00011999 hsa-miR-26a 5.49 8.36E-05 2.80 Under 2.07 
A_25_P00012038 hsa-miR-101 5.91 4.25E-05 3.82 Under 2.26 
A_25_P00010474 hsa-miR-100 4.97 1.98E-04 1.54 Under 2.59 
A_25_P00010980 hsa-miR-125b 4.98 1.96E-04 1.58 Under 3.12 
A_25_P00013852 hsa-miR-30a 7.70 3.23E-06 7.92 Under 4.15 
 
 
3.5 Discussion 
Definitive treatment of OSCC often involves surgical resection, with radiotherapy and/or 
chemotherapy as adjunctive therapies [80]. To improve prognosis, the diseased tissue should be 
excised with a ‘clear’ or ‘clean’ margin – specifically, a margin that has at least 5 mm of 
histologically normal epithelium [70,81,82]. However, delineating the ideal surgical margin is 
difficult with white light examination alone, as clinically- and even histopathologically-determined 
normal mucosa may still contain premalignant changes at a molecular scale [83]. Furthermore, 
interpretation of histology is subjective and there can be intra- and inter-observer variation with 
reporting [84]. Inaccurate assessment of resection margins can lead to an increased risk of cancer 
recurrence and shorter overall survival [81,83,85], and thus there is a need for technologies that can 
aid the accurate assessment of resection margins. NBI is a technology that is increasingly 
demonstrating its value for delineating negative resection margins in the oral cavity [21,35]. 
Therefore, mapping mRNA and miRNA expression profiles at primary OSCC tumour margins 
defined by NBI may provide a better understanding of malignant progression, recurrence and risk 
prediction of OSCC.   
In this study, a total of 4 794 genes and a total of 137 miRNA from 18 tumour samples were 
identified to be significantly DE in one or more of the three tissue groups. There was a first 
discriminatory component separating tumour samples from WL and NBI samples in both miRNA 
and mRNA datasets, which indicates that a molecular difference exists between the tumour core and 
resection margins. However, not only were there more genes differentially expressed in the tumour 
relative to NBI tissues than in the tumour relative to WL, there was also a clearer separation 
between NBI samples from tumour samples on the PCA plots for miRNA and mRNA. Both these 
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findings suggest that tissue taken at the NBI margin contained less molecularly abnormal residual 
tissue than tissue taken from the WL margin.  
The concept that the NBI margin is likely to contain molecularly healthy tissue is supported by the 
fact that the most highly up-regulated genes in NBI samples were associated with normal muscle 
structure and function. In contrast, the majority of genes involved in GO associations were down-
regulated in the tumour core, and this is consistent with the cellular changes that occur in tumours. 
Tissue complexity is reduced in tumours due to the hyperproliferation and impaired cellular 
differentiation that occurs as a result of dysregulation of cell cycling. These changes can occur from 
aberrations in both miRNA and mRNA expression. 
Of the 28 miRNAs with a significant mRNA interaction in the integration dataset, seventeen (let-7c, 
miR-17, miR-21, miR-24, miR-25, miR-26a, miR-26b, miR-30a, miR-30c, miR-31, miR-93, miR-
100, miR-125b, miR-130b, miR-132, miR-181a, miR-224) have previously been identified as being 
differentially expressed in head and neck tumours [86-89]. In addition, four miRNAs (miR-7, miR-
101, miR-218 and miR-222) have been found to be associated with head and neck cancers using 
cell lines [90-93]. Differences in miRNA profiles amongst all the head and neck cancer miRNA 
profile studies may be attributed to variations in stage, grade and anatomical site of the samples 
used, technical issues, and the use of cell lines [88].  
One of the most notable miRNAs involved in a variety of cancers is miR-21, which was also the 
most up-regulated miRNA between the tumour and NBI margin in this study. Our finding of miR-
21 up-regulation and its significant pairing with the protein-coding gene, NFIB, is consistent with 
another study that noted miR-21 over-expression leading to NFIB inhibition in breast cancer [94]. 
NFIB is a validated target of miR-21[95,96], and the double-negative feedback loop between the 
two has been postulated to play a role in regulating differentiation [95]. However, research 
regarding the interaction between miR-21 and NFIB is limited, and its role in oral cancer remains 
unclear.  
The second most up-regulated miRNA that was included in the integration dataset was miR-31, 
which had a fold change of 3.23. Up-regulation of miR-31 in OSCC has previously been reported in 
other studies [88,97], and is particularly involved in early stage OSCC where there is no lymph 
node involvement [97]. Increased expression of miR-31appears to inhibit tumour suppressor genes 
to promote oncogenic pathways that causes proliferation and tumorigenicity of oral cancer. One of 
the biological pathways that miR-31 has been noted to be significantly involved in is the regulation 
of epithelial to mesenchymal transition, which in this study was the most significantly represented 
pathway for both the NBI-T and WL-T miRNA comparisons. Other biological pathways that miR-
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31 has previously been reported to be involved in include the regulation of G1/S transition, GM-
CSF signalling, cytoskeletal remodelling, and remodelling of TGF and WNT [97]. Both MCM4 and 
UBA6 were found to interact with miR-31 in this study, with MCM4 required for initiating 
eukaryotic genome replication in the cell cycle and UBA6 to activate ubiquitin, which is involved in 
post-translational modification. Therefore, whilst the relationship between UBA6 and MCM4 with 
miR-31 in cancer has not been previously described in the literature, these two relationships are 
plausible in OSCC. miR-130b was also up-regulated in the tumour, and has previously been found 
to be up-regulated in gastric and liver cancers [98,99]. However, other studies have reported its 
down-regulation in ovarian and thyroid cancers [100,101]. These conflicting results may be 
attributed to the hypothesis that miRNA profiles are different depending on the type of cancer 
[102]. Nonetheless, miR-130b had a significant relationship with PTPN11, an oncogene belonging 
to the SH2-domain-containing family of genes involved in regulating the activation of the 
MAPK/ERK signalling pathway [103]. Defects in this pathway have previously been reported to 
lead to uncontrolled growth and cancer development [104]. Based on existing literature, miR-130b 
appears to indirectly interact with PTPN11 via the SDF-1/CXCR4/SP-2 pathway. 
The most down-regulated miRNA between the tumour and NBI margin in this study was miR-30a. 
Whilst down-regulation of miR-30a in this study contrasts with a previous report of miR-30a up-
regulation in squamous cell carcinoma of the tongue [89], miR-30a down-regulation has been 
associated with metastatic nasopharyngeal, breast, lung, bladder, colon, and hepatocellular cancers 
[105-107]. miR-30a is therefore associated with regulating metastasis in cancers, and its expression 
level is influenced by the cancer staging of the sample. Nonetheless, its significance in oral cancer 
still needs to be elucidated. In this study, miR-30a had a significant relationship with the LIMCH1 
and PSME4 genes. Over-expression of the cancer-related gene involved in metal ion binding, 
LIMCH1, has been reported when PIK3CA is mutated in breast cancer [108]. In contrast, PSME4 
levels appear to affect tumour cell survival after radiation exposure – namely, higher levels will 
allow cells to maintain glutamine homeostasis, restrict growth, and survive in an environment 
where there is increased cellular demand for exogenous glutamine [109]. 
One significantly differentially expressed miRNA in the dataset known to inhibit tumour growth 
and metastasis in healthy tissue is miR-26a. Under-expression of miR-26a has previously been 
reported in oral cancer as well as a variety of other cancers such as nasopharyngeal carcinoma, 
melanoma, gastric, liver and prostate cancers [110-113], and thus its down-regulation in tumour 
samples in this study was unsurprising. Of the relationships found in this study, only CPEB3 and 
HMGA1 are known targets of miR-26a [114,115]. As a consequence, aberrant expression of miR-
26a will have a downstream effect on its gene targets and result in abnormal biological processes. 
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With CPEB3 involved in translational control and HMGA1 involved in cell cycle transition and cell 
motility [114,115], the under-expression of miR-26a can deregulate translation, enhance malignant 
transformation, cause cancer cell proliferation and increase the risk of metastasis. Furthermore, of 
the other genes found to have a significant interaction with miR-26a, MFHAS1 is a known 
oncogene [116], and OGT modulates metabolic reprogramming, contributes to cell proliferation, 
induces angiogenesis, promotes anti-apoptosis pathways, cancer cell invasion and metastasis in 
cancers [117]. Further research is required to not only verify these genes as miR-26a targets in 
OSCC, but also investigate the effects these relationships have on tumorigenesis and clinical 
prognosis. 
Down-regulation of miR-101 in the tumour was also found in this study, and this is consistent with 
other studies that have reported miR-101 under-expression in hepatocellular carcinoma, colorectal 
and gastric cancer to name a few [118-120]. Considered a tumour suppressor, proposed functions 
for decreased expression of miR-101 include promoting tumorigenicity, suppressing apoptosis, cell 
migration and invasion [118-120]. In this study, miR-101 was found to be significantly paired with 
AP1S3 and NR2F2, although the relationship between both these genes with miR-101 specifically 
in oral cancer has not previously been explored. AP1S3 is involved in protein transporter activity 
and as there have been very limited studies investigating its function, the role it has in cancer has 
yet to be determined. The involvement of NR2F2 in other cancers has however been documented in 
various studies as NR2F2 is known to be involved angiogenesis, tumorigenesis and for regulating 
cell migration and invasion. Studies have reported that increased expression of NR2F2 resulted in 
cell growth, angiogenesis, invasiveness and an overall poor prognosis in pancreatic, prostate and 
colorectal cancers [121-123]. In contrast, decreased expression of NR2F2 was found in ovarian 
cancer [124]. These conflicting levels of expression in different cancers suggest that NR2F2 has 
different roles depending on the type of cancer – either a tumour promoter or a tumour suppressor.  
Another down-regulated miRNA with tumour suppressive activity was miR-218, and this finding is 
consistent with a previous study that reported miR-218 down-regulation in oral cancer [92]. Under-
expression of miR-218 has previously been found to increase levels of the rapamycin-independent 
companion of mTOR (RICTOR) gene which promotes the TOR-Akt signalling pathway [92,125]. 
Growth is partly controlled by the TOR-Akt signalling pathway, and thus aberrant activation of this 
pathway can lead to oral carcinogenesis [88,92]. However, miR-218 is also an osteo-miR involved 
in regulating osteogenic differentiation of various stem cells via the Wnt signalling pathway [126]. 
The Wnt signalling pathway is involved in many biological processes and has been implicated in 
cancer when mutation or deregulation of its components occurs [127]. Known inhibitors of the Wnt 
pathway includes direct targets SOST, DKK2 and SFRP2 [128], all of which were found to be 
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differentially expressed and significantly paired with miR-218 in this study. However, in contrast to 
this study, Hassan et al. reported that up-regulation of miR-218 lead to under-expression of SOST, 
SFRP2 and DKK2, an increase in Wnt signalling, and promotion of breast cancer osteo-mimicry in 
metastatic breast cancer cells [126]. As bone mass, bone regeneration and osteogenic differentiation 
is increased when there is elevated miR-218 expression and Wnt signalling [126,129], it is possible 
that decreased expression of miR-218, and thus inhibition of the Wnt signalling pathway, may be 
associated with bone invasion and destruction in oral cancer. 
The specific processes for abnormal miRNA expression in cancers is still unclear, however, their 
cytogenetic location may be a factor if they are located in either a fragile site or a genomic region 
associated with cancer [86]. Alterations such as rearrangement, point mutations, amplifications and 
deletions in chromosomes 3, 9, 11 and 17 are known to be characteristic of oral and head and neck 
squamous cell carcinomas [130]. In fact, loss of heterozygosity has been reported in 50% of oral 
cancers at 11q [130], and rearrangements at this location have previously been noted in head and 
neck cancers [131]. The fact that several miRNAs such as let-7c, miR-25, miR-17 and miR-93 were 
located in regions associated with cancer suggests that expression levels of both miRNA and 
mRNA can be altered by genomic changes [86]. Furthermore, miRNAs can be clustered together 
when two or more miRNAs are located within short distances of one another on the same 
chromosome [132] Most of the miRNAs within a cluster are co-expressed, and together can co-
ordinately target multiple proteins of a pathway or biological process to produce a combined overall 
effect of a larger pathway or biological process [133].  
Depending on the type of miR-125b, miR-125b may belong in one of two clusters: miR-99a/let-
7c/miR-125b-1 cluster on chromosome 21, or miR-100/let-7a-2/miR-125b-1 cluster on 
chromosome 11. In this study, both miR-100 and miR-125b were down-regulated, and this is 
consistent with previous studies [86,88,134]. Down-regulation of these miRNAs has been 
postulated to promote the development of OSCC, as transfection of OSCC cells with miR-100 and 
miR-125b resulted in decreased cell proliferation and altered expression of target and non-target 
genes [134]. The only gene pairing for miR-100 in this study was with ATP1A2, which is involved 
in creating the sodium and potassium ion exchange across plasma membranes for signalling. Under-
expression of ATP1A2 has previously been reported in neuroblastomas [135]; however, its 
relationship with miR-100 has yet to be investigated. Conversely, miR-125b had several target 
genes in this study, with SUPT6H and NNT implicated in other cancers. .  In breast cancer, 
SUPT6H is required for cellular differentiation and for regulating oestrogen receptor alpha, an 
important breast cancer prognostic marker. Expression of SUPT6H is significantly reduced in 
malignant breast cancer [136]; however, its role in oral cancer has yet to be elucidated. Although 
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the role of NNT in oral cancer also requires investigating, this gene regulates glucose catabolism 
and acts as a free radical detoxifier in the mitochondrion. NNT under-expression increases glucose 
catabolism, and this facilitates the growth and proliferation of cancer cells which have a high 
demand for glycolysis and the glutamine maintained tricarboxylic acid cycle [137].  
Apoptosis and cell migration can be regulated by miR-183, which was up-regulated in this study. 
This is consistent with other studies that have reported elevated expression of miR-183 in 
medulloblastoma, gastric and prostate cancers [138-140]. In fact, miR-183 belongs to the miR-
183/96/182 cluster located on chromosome 7, and the whole cluster can be over-expressed in some 
tumours to synergistically inhibit apoptosis, promote proliferation, cell migration and invasion 
[138-141]. Of the genes paired with miR-183 in this study, only PHPT1 and its involvement in 
cancer has been extensively explored. PHPT1 is an oncogenic protein tyrosine phosphatase that is 
associated with regulating cell differentiation and the EMT pathway [142]. Interestingly, the only 
significant pathway in both the NBI-T and WL-T comparisons was the inhibition of the EMT 
pathway, which can be influenced by expression levels of both miR-183 and PHPT1 [140,142]. 
EMT is a variation of cell differentiation, and therefore aberrations in the regulators for EMT can 
result in tumour metastasis as cells can obtain the ability to migrate and invade [142]. 
Another known miRNA that is involved in apoptosis, cell growth, migration and invasion is  
miR-224. This miRNA is part of the miR-224/miR-452 cluster, and the direction of expression 
appears to vary depending on the type of cancer with the cluster reportedly been over-expressed in 
malignant melanoma but under-expressed in prostate cancer [143,144]. Whilst the role of miR-224 
alone in OSCC has not been explored much, it is one of the most commonly over-expressed 
miRNAs in hepatocellular carcinoma [145]. In this study, miR-224 was also up-regulated in the 
tumour; however, a previous study that investigated the miRNA expression profiles of 15 OSCCs 
using microarray analysis reported miR-224 under-expression [146]. This difference may be due to 
the natural variation in tumour samples, and more research with a larger number of oral tumour 
samples is required to determine the general trend of expression for miR-224 in OSCC and its direct 
functional targets. There was only one gene significantly paired with miR-224 in this study, EYA4. 
Expression of this gene has not previously been reported in OSCC; however, knockdown of EYA4 
is associated with reduced prognosis and increased familial cancer risk in lung cancer and 
hepatocellular carcinoma [147,148]. EYA4 also regulates apoptosis and DNA repair [148], and 
therefore may contribute to the apoptotic effects of miR-224. 
The spectrum of pathophysiological mechanisms involved in cancer is best investigated with the 
use of primary tissues rather than cell lines [102]. In this study, tumour samples were used as this 
enabled the detection of clinically relevant miRNA biomarkers, whereas this would have been 
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restricted with cell lines [149]. Direct comparison was also possible in this study as three samples 
were taken from three separate sites of each tumour used for gene profiling.  The power of direct 
comparison outweighed any variability in patient factors, specifically the genetic and environmental 
influences that may have affected gene expression. Nonetheless, relationships between miRNA and 
mRNA were not validated experimentally as it was beyond the scope of this study. It is also well 
known that the capability for GeneGo to map miRNA is not very strong and therefore the network 
maps should be interpreted with a degree of caution. Findings from this study serve as the basis for 
future research involving the assessment of direct interactions between miRNA and their suggested 
targets in oral cancer. Knowledge of the processes involved in oral cancer can also potentially lead 
to development of therapeutic targets. 
 
 
3.6 Conclusions 
There is a difference in both miRNAs and genes at the tumour compared to the NBI margin. 
miRNAs influence the expression of target mRNAs, and can result in either tumour suppression or 
tumorigenesis depending on which genes are up- or down-regulated. Several over- and under-
expressed miRNAs and genes have previously been implicated in anti-apoptosis, tumorigenesis and 
metastasis in other cancers, and it is therefore possible that they may have the same role in OSCC. 
Future research is required to experimentally validate the interactions between miRNA and mRNA 
pairs so that they may be used as biomarkers for cancerous tissue. The use of NBI to delineate 
surgical margins may also improve the success rate of OSCC treatment as the NBI margin appears 
to contain less molecularly aberrant cells. 
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CHAPTER 4 
 
General discussion and conclusions
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4.1 Introduction 
This thesis has contributed to the field of oral cancer in several ways. Studies regarding the efficacy 
and applications of Narrow Band Imaging (NBI) in the oral cavity are quite limited; however, the 
existing literature supports the idea that detection and assessment of dysplasia and oral squamous 
cell carcinoma (OSCC) can potentially be improved with the use of NBI.  
Previous research has not focussed specifically on the use of NBI on a range of oral potentially 
malignant disorders (OPMDs) [44], and this is the first time that the clinical use of NBI for the 
detection of OPMDs has been prospectively evaluated. OPMDs, as defined by the World Health 
Organisation, include a broad range of oral mucosal disorders that have the ability to progress to 
cancer [40]. By investigating the effectiveness of NBI on different types of OPMDs, the value of 
NBI and its role in oral cancer detection could be further elucidated. In this study, NBI had a high 
diagnostic accuracy for aiding the detection of OPMDs, and highlighted lesions that were not 
identified by conventional oral examination (COE) or white light (WL) examination.  
The improved visualisation of lesions, particularly of the underlying microvasculature, has also 
resulted in better delineation of lesion margins. Molecular studies of margins have yet to assess 
NBI-determined margins, and this paper is also the first to integrate the microRNA (miRNA) and 
mRNA expression profiles of tissues taken at tumour, WL margins and NBI margins. Of note is the 
inclusion of the molecular profile at the NBI margin which was clearly segregated from that of the 
tumour, thus suggesting that tissue at the NBI margin is likely to be molecularly ‘normal’. Results 
from this thesis will provide a foundation for further research that is required to improve how NBI 
can be utilised in the oral cavity. 
 
 
4.2 Clinical implications with the use of Narrow Band Imaging 
Both the white light (WL) and NBI modalities of a commercial NBI system improved the 
visualisation of lesions and aided the detection of lesions undetected by COE. This was 
unsurprising as NBI had the ability to access hidden niches with the endoscope, strong 
magnification and physical zoom properties, and could project images onto a high definition 
monitor. The filtered blue and green lights provided a contrast that enhanced subtle changes in both 
the mucosal surface texture and the microvascular morphology of lesions, thus making lesions 
clearer with NBI than with WL, and notably more so than by COE. Improved visualisation with 
NBI resulted in a detection rate of OPMDs that was superior to both COE and WL. When compared 
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to COE, NBI had very high accuracy for the clinical detection of OPMDs. This is consistent with 
previous studies that have reported improved visualisation and detection rates with NBI [24,28,29]. 
Lesions are therefore less likely to be missed with NBI, provided that a full exam of the oral cavity 
is conducted. 
One of the key issues with many existing visualisation adjuncts is the poor ability to differentiate 
benign lesions from disease. When compared to both COE and WL clinical diagnoses, NBI had 
very high sensitivity, suggesting that the use of NBI has a low rate of false negatives. Whilst 
specificity was lower, it was still reasonably high when compared to both clinical and 
histopathological diagnoses, thereby suggesting that NBI also has a fairly low rate of false positives. 
The rates of false positives and negatives were low despite the fact that there was no statistical 
association between IPCL pattern of OPMDs and pathological diagnoses. This can be attributed to 
the fact that a specialist with extensive knowledge of oral pathology and previous training with 
using NBI conducted all examinations. Without this knowledge, the efficacy would most likely be 
reduced. Hence, use of NBI should be limited to those trained to use NBI in specialist or tertiary 
referral centres that see and treat higher numbers of patients with oral mucosal pathology. 
OPMDs have the ability to progress to cancer, and should therefore be regularly monitored so that 
treatment can be instigated before they become cancerous. Thus far, no visualisation adjunct can 
accurately assess progressive from non-progressive lesions [32,44]. Whilst assessing this property 
was beyond the scope of this thesis as it requires a longitudinal study, NBI could very easily be 
useful for monitoring lesions due to its ability to aid the assessment of small changes in both the 
mucosal surface and underlying microvasculature, and its video recording capability. Although not 
as clear as the live video feed, the video recordings of the NBI system still provides a higher 
magnification record than extraoral photographs and is of ample quality for clinicians to review and 
reassess IPCL patterns of lesions. Every time an examination is conducted with an NBI system, a 
recording of both the WL and NBI examinations should therefore be undertaken for future review 
and comparison. 
The extent of some lesions was found to be greater with NBI than determined by COE and WL. 
This was demonstrated best in the third chapter, which found that tissue at the NBI-determined 
margin was healthier on a molecular level than tissue determined by WL. Clinically, this improved 
visualisation can have a significant impact on how both OPMDs and OSCCs are biopsied and 
surgically removed. For biopsies, usually the most severe part of oral lesions is sampled so that the 
lesion can be treated according to the worst diagnosis. Based on COE findings, these may be areas 
of significant non-homogeneous leukoplakia, erythroplakia, erythroleukoplakia, erosion or 
ulceration. However, when more than one area displays any one of these signs, the clinician has two 
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options: use their clinical knowledge and experience to select the site that is most likely to be the 
most severe, or to take multiple biopsies. Incorrect sampling may lead to under-diagnosis and 
inadequate treatment, and this may then potentially result in lesions progressing to OSCC. Whilst 
there is evidence that multiple biopsies reduces the rate of under-diagnosis [52], the cost and 
discomfort inflicted onto the patient is greater. NBI can guide the clinician in selecting the best 
biopsy site based on the area with the most severe intrapapillary capillary loop (IPCL) pattern, 
thereby minimising the need to take multiple biopsies.  
In the event where surgical removal is required, clean surgical margins are required to reduce the 
risk of recurrence. The current standard for determining margins is with WL; however, this may not 
result in disease-free margins at a molecular level despite appearing histologically clear [83]. NBI 
can aid the delineation of clean surgical margins as its ability to highlight changes in the surface 
texture and underlying microvasculature improves the clinician’s ability to differentiate healthy 
tissue from diseased. The third chapter demonstrated that an NBI-determined margin had healthier 
tissue than WL-determined margins. For both miRNA and mRNA, the distinction between the 
molecular profile between tissues taken at the tumour site and those taken from the NBI margin was 
more apparent than between the tumour and WL margins. This suggests that margins defined by 
NBI are more molecularly ‘normal’ than those defined by WL, and that there is a cancer to 
dysplasia to healthy tissue continuum from the tumour to WL margin and NBI margin. The 
potential clinical impact of this finding is great – specifically, the use of NBI for determining 
surgical margins instead of WL could provide a cleaner margin and thus improve the long term 
prognosis of patients as the risk of recurrence is lowered. 
 
 
4.3 Molecular insights  
As previously mentioned, there was a clear separation between the tumour and margins defined by 
WL and NBI for both miRNA and mRNA expression; however, this separation was more 
noticeable between the tumour and NBI. This suggests that NBI is more likely to have less minimal 
residual disease than WL. By comparing expression of miRNA and mRNA between tumour and 
margins, particularly the NBI margin, key molecular changes associated with tumorigenesis can be 
identified. For example, genes associated with normal tissue structure and function were up-
regulated in tissue taken from the NBI-defined margins but were down-regulated in the tumour. 
Aberrant expression patterns such as these support the fact that tumours have less complex tissue 
structure than healthy tissues. 
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To gain a better understanding of the interplay between miRNA and mRNA, this study correlated 
both miRNA and mRNA expression at the OSCC tumour core with margins defined by WL and 
NBI. A total of 91 potential miRNA-mRNA pairs were identified between 28 miRNAs and 87 
genes. The majority of miRNAs identified in the dataset have been previously linked to head and 
neck cancers and their direction of expression (i.e. over-expression or under-expression) in this 
study were largely consistent with other studies. Of note was the most up-regulated miRNA in this 
study, miR-21, which is widely known to be up-regulated in cancers and has been reported to be up-
regulated in oral lichen planus as well [102]. Other miRNAs that were up-regulated in this study 
that have also been reported to be up-regulated in oral lichen planus include miR-31 and miR-132 
[102]. It is possible that these may be markers for increasing the risk of developing OSCCs from 
oral lichen planus, particularly since miR-31 is associated with early-stage cancer where there is no 
lymph node involvement. These miRNAs may be used as biomarkers for lesions that are 
undergoing tumorigenesis. 
The general trend for the majority of the most over- and under-expressed miRNAs in the third 
chapter was their involvement in tumour growth and metastasis. Whilst the up-regulation of  
miR-31, miR-183, miR-224 have been implicated in promoting tumorigencity, anti-apoptotic 
pathways, cell mobility and/or invasion in various cancers, it was the reverse for miR-26a, miR-31a, 
miR-100, miR-101 and miR-125b. However, as miRNAs are regulators of the translation and 
transcription of gene expression, the genes the miRNAs interact with are likely to have similar 
actions, and this was evident in several of the miRNA-mRNA pairs in this study. For example, 
under-expression of miR-26a deregulates translation, enhances malignant transformation, and 
promotes cell proliferation and metastasis. Two direct and functional targets of miR-26a in this 
study were CPEB3 and HMGA1, with CPEB3 involved in translational control and HMGA1 
involved in cell cycle transition and cell mobility. Although the majority of miRNA-mRNA pairs 
are not validated direct and functional targets of the miRNAs, several of the target genes have also 
been identified in various cancers. The identification of these miRNAs and genes not only supports 
their role in cancer, but also allows for further research into identifying biomarkers specifically for 
oral cancer and disease progression through dysplasia. 
Genomic location of miRNAs and mRNAs may also be used to determine if an OPMD will 
progress to OSCC. Aberrations in chromosomes 3, 9, 11 and 17 are associated with oral and head 
and neck squamous cell carcinomas [130]. Any miRNAs or mRNAs expressed in an OPMD that is 
located on one of these chromosomes could therefore be a potential biomarker for disease 
progression. Furthermore, miRNAs within the same cluster typically promote similar effects and 
thus the identification of one miRNA from a cluster could implicate another miRNA within the 
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same cluster being aberrantly expressed in an OPMD or OSCC. Known target genes for any 
miRNA within the cluster should be investigated as well, as these may contribute to tumorigenic 
activity and can therefore be potentially used as biomarkers or therapeutic targets.  
Although only nine pairs have previously been verified to have a direct relationship, identification 
of the other pairs provides possible interactions that should be further investigated. Less than half 
the interactions were part of known canonical pathways, which suggests that results from this study 
are only a portion of what is undoubtedly a larger and more complex pathway map for oral cancer. 
Knowledge of the molecular processes involved in oral cancer will enable a better understanding of 
the disease, and can direct areas that require future research. 
 
 
4.4 Future directions and conclusions 
NBI has the potential to be a useful visualisation adjunct for monitoring OPMDs due to its video 
recording capability and its ability to highlight small changes in both mucosal surface texture and 
submucosal microvasculature. Longitudinal studies are required to fully assess how effective NBI is 
for monitoring lesions, and if it can aid the differentiation between progressive and non-progressive 
lesions. A proportion of patients from the first chapter are currently being reviewed and therefore, 
results from this study can form the foundation for future work regarding the assessment of NBI for 
monitoring OPMDs.  
The current study did not primarily focus on determining associations between clinical NBI 
findings and histopathology of the OPMDs observed. Comparisons were primarily based on clinical 
findings as the focus was to clinically compare NBI with existing clinical gold standards. As such, 
the study utilised a uniform ‘soft’ clinical gold standard instead of the ‘hard’ gold standard, 
histopathology. Further research investigating the types of mucosal and vascular changes in a range 
of OPMDs and how they correspond to histopathology is necessary for improving the interpretation 
of lesions by NBI.  
Use of IPCL patterns to evaluate lesions is subjective in nature. Research to assess the molecular 
changes that occur for each IPCL pattern may improve our understanding of the types of lesions 
that may be associated with a particular IPCL pattern. In particular, given how IPCL patterns do not 
distinctly correspond with pathological diagnoses of OPMDs, research into the molecular profiles 
of OPMDs and how these profiles correspond to IPCL patterns may possibly enable the 
development of a more objective classification system. Indeed in the current study, we instigated a 
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Type 0 IPCL pattern based on the presence of thick keratotic/leukoplakic lesions which prevented 
complete visualization of underlying IPCL. This is important to note as a departure from the IPCL 
classification system developed by Takano[21]. In light of the many keratotic/leukoplakic lesions 
that one encounters in the oral cavity, this addition is meaningful, and we suggest that this should be 
adopted in future research in this area. Although IPCL patterns could not be visualised under such 
lesions, it is still important to note the significant enhancement of topographic alterations of surface 
epithelial changes in OPMDs given the importance of these in determining clinical risk of 
underlying epithelial dysplasia and potential for malignant transformation [54]. 
Furthermore, molecular profiling of OPMDs can be compared with profiles of OSCCs to provide a 
better understanding of the mechanisms that may be involved when OPMDs progress to OSCCs. 
Key biomarkers can also be deduced from these comparisons, which may result in the development 
of therapeutic targets to prevent this progression. 
In this study, differentially expressed genes were not verified in vitro prior to bioinformatics 
integration; instead these were done in silico. Validation of these genes with real-time quantitative 
polymerase chain reaction (RT-qPCR) and immunohistochemistry will further strengthen the results 
from this study. In addition, research into each miRNA and mRNA pair without a validated direct 
interaction relationship is required to support findings from this study. By verifying and validating 
findings from this study, potential biomarkers for oral cancer can be identified and research into 
oral cancer biomarkers can be facilitated. Furthermore, knowledge of miRNA and mRNA 
interactions will also contribute to our understanding of the pathways involved in OSCCs. 
Identification of key pathways involved in oral carcinogenesis will guide future research activity so 
that therapeutic targets can be developed.  
It is clear that NBI shows great potential in improving the detection rates of lesions, facilitating 
better assessment of identified lesions, and reducing the risk of recurrence for lesions that require 
excision. There is building evidence to recommend its use in tertiary institutions and referral clinics 
that need to assess and treat patients with oral mucosal pathologies. 
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Search strategies for systematic literature review
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Pubmed search strategy 
#1 MeSH descriptor narrow band imaging 
#2 MeSH descriptor narrowband imaging 
#3 MeSH descriptor narrow-band imaging 
#4 (#1 OR #2 OR #3) 
#5 MeSH descriptor oral cancer 
#6 MeSH descriptor oral squamous cell 
#7 MeSH descriptor oral squamous carcinoma 
#8 MeSH descriptor oral squamous cell carcinoma 
#9 MeSH descriptor oral tumor 
#10 MeSH descriptor oral malignancy 
#11 MeSH descriptor oral neoplasia 
#12 MeSH descriptor oral neoplasm 
#13 MeSH descriptor oral cavity cancer 
#14 MeSH descriptor oral cavity cancers 
#15 MeSH descriptor cancer oral cavity 
#16 MeSH descriptor carcinoma oral cavity 
#17 MeSH descriptor carcinoma oral 
#18 MeSH descriptor oral cavity squamous cell carcinoma 
#19 MeSH descriptor squamous cell carcinoma oral 
#20 MeSH descriptor squamous cell carcinoma oral cavity 
#21 MeSH descriptor squamous cell carcinoma oral cancer 
#22 MeSH descriptor tumor oral cavity 
#23 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR 
#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22) 
#24 MeSH descriptor oropharyngeal cancer 
#25 MeSH descriptor oropharyngeal carcinoma 
#26 MeSH descriptor oropharyngeal squamous 
#27 MeSH descriptor oropharyngeal squamous carcinoma 
#28 MeSH descriptor oropharyngeal squamous cell carcinoma 
#29 (#24 OR #25 OR #26 OR #27 OR #28) 
#30 MeSH descriptor potentially malignant disorders 
#31 MeSH descriptor oral potentially malignant disorders 
#32 MeSH descriptor potentially malignant oral disorders 
#33 MeSH descriptor potentially malignant oral lesions 
#34 MeSH descriptor oral premalignant 
#35 MeSH descriptor oral premalignant lesion 
#36 MeSH descriptor oral premalignant lesions 
#37 MeSH descriptor oral precancerous 
#38 MeSH descriptor oral precancer 
#39 MeSH descriptor oral precancerous lesions 
#40 MeSH descriptor oral leukoplakia 
#41 MeSH descriptor oral leucoplakia 
#42 MeSH descriptor oral erythroplakia 
#43 MeSH descriptor erythroplakia oral 
#44 MeSH descriptor lichen planus 
#45 MeSH descriptor oral lichen 
#46 MeSH descriptor oral lichen planus 
#47 MeSH descriptor submucous fibrosis 
#48 MeSH descriptor oral submucous fibrosis 
#49 MeSH descriptor actinic cheilitis 
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#50 MeSH descriptor discoid lupus erythematosus 
#51 MeSH descriptor discoid lupus erythematosus oral 
#52 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR # 
41 OR #42 OR #43 OR #44 OR #45 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 
OR #52) 
#53 MeSH descriptor detection 
#54 MeSH descriptor surveillance 
#55 (#53 OR #54) 
#56 (#4 AND (#23 OR #29 OR #52) AND #55) Limits: English; Humans 
 
 
EMBASE search strategy 
#1 'narrow band imaging'/exp 
#2 'narrowband imaging'/exp 
#3 'narrow-band imaging'/exp 
#4 (#1 OR #2 OR #3) 
#5 'oral'/syn 
#6 'oral cavity'/syn 
#7 cancer* 
#8 squamous AND cell* 
#9 squamous AND 'carcinoma'/syn 
#10 'tumor'/syn 
#11 malignan* 
#12 neoplas* 
#13 ((#5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12) ) 
#14 'potentially malignant disorders' 
#15 'potentially malignant disorder' 
#16 precancer* 
#17 premalignan* 
#18 'leukoplakia'/syn 
#19 'erythroplakia'/syn 
#20 'lichen planus'/syn 
#21 'submucous fibrosis' 
#22 'discoid lupus erythematosus'/syn 
#23 'actinic cheilitis'/syn 
#24 ((#5 AND (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)) OR (#20 
OR #21 OR #22 OR #23) 
#25 ‘oropharyngeal’ 
#26 ‘carcinoma’/syn 
#27 squamous AND ‘cell’/de AND ‘carcinoma’/syn 
#28 (#25 AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #26 OR #27) 
#29 detect* 
#30 ‘surveillance’ 
#31 (#29 OR #30) 
#32 (#4 AND (#13 OR #24 OR #25) AND #31) AND [humans]/lim AND [English]/lim 
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Web of Science search strategy 
#1 narrow band imaging 
#2 narrowband imaging 
#3 narrow-band imaging 
#4 (#1 OR #2 OR #3) 
#5 oral 
#6 ‘oral cavity’ 
#7 cancer* 
#8 ‘squamous cell*’ 
#9 ‘squamous carcinoma’ 
#10 tumor 
#11 tumour 
#12 malignan* 
#13 neoplas* 
#14 ((#5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 13)) 
#15 oropharyngeal 
#16 (#15 AND ((#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 13)) 
#17 ‘potentially malignant disorder*’ 
#18 precancer* 
#19 premalignan* 
#20 leukoplakia 
#21 leucoplakia 
#22 erythroplakia 
#23 ‘lichen planus’ 
#24 ‘submucous fibrosis’ 
#25 ‘discoid lupus erythematosus’ 
#26 ‘actinic cheilitis’ 
#27 (#5 AND (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25)) OR (#23 
OR #24 OR #25 OR #26) 
#28 detect* 
#29 surveillance 
#30 (#28 or #29) 
#31 (#4 and (#14 or #16 or #27) and #30) and  Language=(English) 
 
 
Scopus search strategy 
#1 TITLE-ABS-KEY-AUTH(narrow band imaging) 
#2 TITLE-ABS-KEY-AUTH(narrowband imaging) 
#3 TITLE-ABS-KEY-AUTH(narrow-band imaging) 
#4 (#1 OR #2 OR #3) 
#5 TITLE-ABS-KEY-AUTH(oral) 
#6 TITLE-ABS-KEY-AUTH(“oral cavity”) 
#7 TITLE-ABS-KEY-AUTH(cancer* 
#8 TITLE-ABS-KEY-AUTH(“squamous cell*”) 
#9 TITLE-ABS-KEY-AUTH(“squamous carcinoma”) 
#10 TITLE-ABS-KEY-AUTH(tumor) 
#11 TITLE-ABS-KEY-AUTH(tumour) 
#12 TITLE-ABS-KEY-AUTH(malignan*) 
#13 TITLE-ABS-KEY-AUTH(neoplas*) 
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#14 ((#5 OR #6) AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 13)) 
#15 TITLE-ABS-KEY-AUTH(oropharyngeal) 
#16 (#15 AND ((#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 13)) 
#17 TITLE-ABS-KEY-AUTH(“potentially malignant disorder*”) 
#18 TITLE-ABS-KEY-AUTH(precancer*) 
#19 TITLE-ABS-KEY-AUTH(premalignan*) 
#20 TITLE-ABS-KEY-AUTH(leukoplakia) 
#21 TITLE-ABS-KEY-AUTH(leucoplakia) 
#22 TITLE-ABS-KEY-AUTH(erythroplakia) 
#23 TITLE-ABS-KEY-AUTH(“lichen planus”) 
#24 TITLE-ABS-KEY-AUTH(“submucous fibrosis”) 
#25 TITLE-ABS-KEY-AUTH(“discoid lupus erythematosus”) 
#26 TITLE-ABS-KEY-AUTH(“actinic cheilitis”) 
#27 (#5 AND (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25)) OR (#23 
OR #24 OR #25 OR #26) 
#28 TITLE-ABS-KEY-AUTH(detect*) 
#29 TITLE-ABS-KEY-AUTH(surveillance) 
#30 (#28 or #29) 
#31 (#4 and (#14 or #16 or #27) and #30) AND (LIMIT-TO(EXACTKEYWORD, “Human”) OR 
LIMIT-TO(EXACTKEYWORD, “Humans”)) AND (LIMIT-TO(LANGUAGE, “English”)) 
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APPENDIX II 
 
Individual images from Figure 2.2 
 
87 
 
 
Figure II.1. Image (a), WL image of leukoplakia on gingiva. 
 
 
Figure II.2. Image (b), NBI image of leukoplakia on gingiva. 
IPCL type 0 pattern as IPCL pattern cannot be seen within the keratotic area 
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Figure II.3. Image (c), WL image of leukoplakia on hard palate. 
 
 
Figure II.4. Image (d), NBI image of leukoplakia on hard palate. 
IPCL type 0 pattern as IPCL pattern cannot be seen within the keratotic area. 
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Figure II.5. Image (e), WL image of leukoplakia on buccal mucosa. 
 
 
Figure II.6. Image (f), NBI image of leukoplakia on buccal mucosa. 
Type I IPCL pattern can be seen where there is thin or no keratosis. Red arrows mark where images (g) and (f) are 
located. 
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Figure II.7. Image (g), Magnification from area in image (f) where the type I pattern consists of 
regular brown dots. 
 
 
Figure II.8. Image (h), Magnification from area in image f where the type I pattern consists of 
waved lines. 
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Figure II.9. Image (i), WL image of ulcerated lesion on buccal mucosa in a patient with oral lichen 
planus. 
 
 
Figure II.10. Image (j), NBI image of ulcerated lesion on buccal mucosa in a patient with oral lichen 
planus. 
Type II IPCL pattern can be seen surrounding the fibrin centre, which appears pink on NBI. 
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Figure II.11. Image (k), WL image of lichenoid lesion on lateral tongue. 
 
 
Figure II.12. Image (l), NBI image of lichenoid lesion on lateral tongue. 
Type II IPCL pattern can be seen surrounding the fibrin centre where there is less keratosis. 
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Figure II.13. Image (m), WL image of non-homogeneous leukoplakia on lateral tongue extending 
into floor of mouth. 
 
 
Figure II.14. Image (n), NBI image of non-homogeneous leukoplakia on lateral tongue extending 
into floor of mouth. 
Type III IPCL pattern can be seen where there is thin or no keratosis. Red arrows mark where images (o) and (p) are 
located.  
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Figure II.15. Image (o), Magnification from area in image (n) demonstrating the elongated and 
meandering characteristics of type III IPCL pattern. 
 
 
Figure II.16. Image (p), Magnification from area in image (n) demonstrating the elongated and 
meandering characteristics of type III IPCL pattern. 
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Figure II.17. Image (q), WL image of squamous cell carcinoma on soft palate. 
 
 
Figure II.18. Image (r), NBI image of squamous cell carcinoma on soft palate. 
Several types of IPCL patterns can be seen; however, type IV IPCL pattern located by the red arrow was the worst 
pattern present and therefore the pattern assigned to the lesion. The red arrow marks where image (s) is located. 
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Figure II.19. Image (s), Magnification from area in image (r) with type IV IPCL pattern. 
Angiogenesis and IPCL pattern destruction present. 
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APPENDIX III 
 
miRNA-mRNA GeneGo networks 
(Gradient mode) 
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Figure III.1. let-7c, RALGAPA2, HMGA2, BPTF, CCNB2, CCNF, DUSP7 and NUPL1 network. 
This network was created with let-7c up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.2. miR-7, COLEC12, and EFHD2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.3. miR-17, HSPB2, EIF4G3, DNAJC27, ENPP5, OPTN, and KDM4A network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.4. miR-18b, TIMP3, CDCA5, and RBMS2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.5. miR-21 and NFIB network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.6. miR-23b, ATXN10, and CPEB3 network. 
This network was created with miR-23b up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.7. miR-24, CCNA2, and SLC7A2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.8. miR-25 and PDGFRL network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.9. miR-26a, CPEB3, HMGA1, MFHAS1, KIAA1704, OGT, and SFMBT1 network. 
This network was created with miR-26a up-regulation as a reference; however, it was down-regulated in this study. Key miRNAs and mRNAs are highlighted with a blue shaded 
circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
107 
 
 
Figure III.10. miR-26b, CACNB2, ZNF652, HECA, CHD9, NAA50, and PDK1 network. 
This network was created with miR-26b up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.11. miR-30a, PSME4, and LIMCH1 network. 
This network was created with miR-30a up-regulation as a reference; however, it was down-regulated in this study. Key miRNAs and mRNAs are highlighted with a blue shaded 
circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.12. miR-30c, DLC1, and SOCS3 network. 
This network was created with miR-30c up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.13. miR-31, UBA6, and MCM4 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.14. miR-93 and DCTN1 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.15. miR-100 and ATP1A2 network. 
This network was created with miR-100 up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.16. miR-101, NR2F2, and AP1S3 network. 
This network was created with mir-101 up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
 
  
114 
 
 
Figure III.17. miR-103a and FKBP1A network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.18. miR-125b, C2orf88, MRTO4, NNT, and SUPT6H network. 
This network was created with miR-125b up-regulation as a reference; however, it was down-regulated in this study. Key miRNAs and mRNAs are highlighted with a blue shaded 
circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.19. miR-130b and PTPN11 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.20. miR-132, SEC61A1, FRY, VPS13D, GK, THBS1, SAMSN1, and OAS2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.21. miR-181a, IQCG, BRCA1, PHPT1, WNT2, TMEM192, and SRPK2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.22. miR-183, PTPN11, UBXN7, and RC3H2 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.
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Figure III.23. miR-193b, LMCD1, and EPPK1 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.24. miR-196a, PRUNE2, and IGF2BP3 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
122 
 
 
Figure III.25. miR-218, ARSG, CDK6, RNF38, SOST, ZNF711, AGPAT5, CNTNAP2, KLF9, 
DKK2, and SFRP2 network. 
This network was created with miR-218 up-regulation as a reference; however, it was down-regulated in this study. Key 
miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and 
down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.26. miR-222, SCARB2, HMGA1, TCOF1, and OLA1 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.27. miR-224 and EYA4 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles 
and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. 
Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure III.28. miR-744, FBN2, and NDE1 network. 
Key miRNAs and mRNAs are highlighted with a blue shaded circle. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents 
activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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APPENDIX IV 
 
miRNA-mRNA GeneGo networks 
(Localisation mode) 
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Figure IV.1. let-7c, RALGAPA2, HMGA2, BPTF, CCNB2, CCNF, DUSP7 and NUPL1 network. 
This network was created with let-7c up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-regulated 
with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to  
Appendix VI for complete legend.  
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Figure IV.2. miR-7, COLEC12, and EFHD2 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure IV.3. miR-17, HSPB2, EIF4G3, DNAJC27, ENPP5, OPTN, and KDM4A network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.4. miR-18b, TIMP3, CDCA5, and RBMS2 network 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.5. miR-21 and NFIB network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure IV.6. miR-23b, ATXN10, and CPEB3 network. 
This network was created with miR-23b up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.7. miR-24, CCNA2, and SLC7A2 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.8. miR-25 and PDGFRL network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.9. miR-26a, CPEB3, HMGA1, MFHAS1, KIAA1704, OGT, and SFMBT1 network. 
This network was created with miR-26a up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
136 
 
 
Figure IV.10. miR-26b, CACNB2, ZNF652, HECA, CHD9, NAA50, and PDK1 network. 
This network was created with miR-26b up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.11. miR-30a, PSME4, and LIMCH1 network. 
This network was created with miR-30a up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.12. miR-30c, DLC1, and SOCS3 network. 
This network was created with miR-30c up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.13. miR-31, UBA6, and MCM4 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.14. miR-93 and DCTN1 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.15. miR-100 and ATP1A2 network. 
This network was created with miR-100 up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.16. miR-101, NR2F2, and AP1S3 network. 
This network was created with mir-101 up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.17. miR-103a and FKBP1A network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.18. miR-125b, C2orf88, MRTO4, NNT, and SUPT6H network. 
This network was created with miR-125b up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.19. miR-130b and PTPN11 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.20. miR-132, SEC61A1, FRY, VPS13D, GK, THBS1, SAMSN1, and OAS2 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.21. miR-181a, IQCG, BRCA1, PHPT1, WNT2, TMEM192, and SRPK2 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
148 
 
 
Figure IV.22. miR-183, PTPN11, UBXN7, and RC3H2 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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 Figure IV.23. miR-193b, LMCD1, and EPPK1 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.24. miR-196a, PRUNE2, and IGF2BP3 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.25. miR-218, ARSG, CDK6, RNF38, SOST, ZNF711, AGPAT5, CNTNAP2, KLF9, DKK2, and SFRP2 network. 
This network was created with miR-218 up-regulation as a reference; however, it was down-regulated in this study. Up-regulated genes are marked with red circles and down-
regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical pathways. Refer to 
Appendix VI for complete legend.  
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Figure IV.26. miR-222, SCARB2, HMGA1, TCOF1, and OLA1 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.27. miR-224 and EYA4 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.  
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Figure IV.28. miR-744, FBN2, and NDE1 network. 
Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick cyan 
lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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APPENDIX V 
 
Merged miRNA-mRNA GeneGo networks 
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Figure V.1. Merged miR-23b and miR-26a networks (gradient mode). 
miR-26a was on the original miR-23b network. This network was created with both miR-23b and miR-26a up-regulation as a reference; however, both were down-regulated in this 
study. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend.
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Figure V.2. Merged miR-23b and miR-26a networks (localisation mode). 
miR-26a was on the original miR-23b network. This network was created with both miR-23b and miR-26a up-regulation as a reference; however, both were down-regulated in this 
study. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line represents activation, red line inhibition, and grey line unspecified. Thick 
cyan lines indicate the fragments of canonical pathways. Refer to Appendix VI for complete legend. 
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Figure V.3. Merged miR-31 and miR-218 networks (gradient mode). 
Both miR-31 and miR-218 had the E2F1-CyclinE-CDK2 path in their networks. This network was merged with both 
miR-31 and miR-218 up-regulation as a reference. However, only miR-31 was up-regulated in this study; miR-218 was 
down-regulated. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line 
represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical 
pathways. Refer to Appendix VI for complete legend.
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Figure V.4. Merged miR-31 and miR-218 networks (localisation mode). 
Both miR-31 and miR-218 had the E2F1-CyclinE-CDK2 path in their networks. This network was merged with both 
miR-31 and miR-218 up-regulation as a reference. However, only miR-31 was up-regulated in this study; miR-218 was 
down-regulated. Up-regulated genes are marked with red circles and down-regulated with blue circles. A green line 
represents activation, red line inhibition, and grey line unspecified. Thick cyan lines indicate the fragments of canonical 
pathways. Refer to Appendix VI for complete legend.
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Legend for Appendices III, IV and V 
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Grouping  Symbol Description 
Data  
 
Up-regulated (+) 
  
 
Down-regulated (-) 
Network objects Channels/transporters 
 
Generic channel 
  
 
Transporter 
  
 
Voltage-gated channel 
 Enzymes 
 
Generic Enzyme 
  
 
RAS – superfamily 
  
 
Generic kinase 
  
 
Protein kinase 
  
 
Protein phosphatase 
  
 
Lipid phosphatase 
  
 
Generic protease 
  
 
Metalloprotease 
 Generic classes 
 
Generic binding protein 
  
 
Protein 
  
 
Receptor ligand 
  
 
Reaction 
  
 
Transcription factor 
 G protein 
adaptor/regulators  
G beta/gamma 
  
 
Regulator 
 Receptors 
 
Generic receptor 
  
 
G protein-coupled receptor 
  
 
Receptor with kinase activity 
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Grouping  Symbol Description 
Groups of objects  
 
A complex or a group that is 
physically connected into a 
complex or is related as a family 
  
 
Logical association whereby 
objects are linked by logical 
relations or physical interactions 
Interactions 
 
Positive / activation effect 
 
 Negative / inhibition effect 
 
 
Unspecified effect 
 
 Canonical pathway 
Adapted from Metacore Quick Reference Guide [150]. 
 
 
